{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:52:11Z","timestamp":1791492731693,"version":"4.3.4"},"reference-count":366,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41401-025-01675-8","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T06:39:28Z","timestamp":1762238368000},"page":"3-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["New advances in small molecule drugs targeting NMDA receptors"],"prefix":"10.1038","volume":"47","author":[{"given":"Yue","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-yan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-wen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-bing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"1675_CR1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.conb.2012.01.007","volume":"22","author":"DL Hunt","year":"2012","unstructured":"Hunt DL, Castillo PE. Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol. 2012;22:496\u2013508.","journal-title":"Curr Opin Neurobiol"},{"key":"1675_CR2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/349156a0","volume":"349","author":"ZI Bashir","year":"1991","unstructured":"Bashir ZI, Alford S, Davies SN, Randall AD, Collingridge GL. Long-term potentiation of NMDA receptor-mediated synaptic transmission in the hippocampus. Nature. 1991;349:156\u20138.","journal-title":"Nature."},{"key":"1675_CR3","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1124\/pharmrev.120.000131","volume":"73","author":"KB Hansen","year":"2021","unstructured":"Hansen KB, Wollmuth LP, Bowie D, Furukawa H, Menniti FS, Sobolevsky AI, et al. Structure, function, and pharmacology of glutamate receptor ion channels. Pharmacol Rev. 2021;73:1469\u2013658.","journal-title":"Pharmacol Rev"},{"key":"1675_CR4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1126\/science.2841759","volume":"241","author":"NW Kleckner","year":"1988","unstructured":"Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 1988;241:835\u20137.","journal-title":"Science."},{"key":"1675_CR5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/309261a0","volume":"309","author":"ML Mayer","year":"1984","unstructured":"Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature. 1984;309:261\u20133.","journal-title":"Nature."},{"key":"1675_CR6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1113\/jphysiol.1987.sp016883","volume":"394","author":"ML Mayer","year":"1987","unstructured":"Mayer ML, Westbrook GL. Permeation and block of N-methyl-D-aspartic acid receptor channels by divalent cations in mouse cultured central neurones. J Physiol. 1987;394:501\u201327.","journal-title":"J Physiol"},{"key":"1675_CR7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1113\/jphysiol.1988.sp017078","volume":"399","author":"P Ascher","year":"1988","unstructured":"Ascher P, Nowak L. The role of divalent cations in the N-methyl-D-aspartate responses of mouse central neurones in culture. J Physiol. 1988;399:247\u201366.","journal-title":"J Physiol"},{"key":"1675_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0092-8674(05)80029-7","volume":"72","author":"HR Bourne","year":"1993","unstructured":"Bourne HR, Nicoll R. Molecular machines integrate coincident synaptic signals. Cell. 1993;72:65\u201375.","journal-title":"Cell."},{"key":"1675_CR9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn3504","volume":"14","author":"P Paoletti","year":"2013","unstructured":"Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383\u2013400.","journal-title":"Nat Rev Neurosci"},{"key":"1675_CR10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nrn1784","volume":"6","author":"D Attwell","year":"2005","unstructured":"Attwell D, Gibb A. Neuroenergetics and the kinetic design of excitatory synapses. Nat Rev Neurosci. 2005;6:841\u20139.","journal-title":"Nat Rev Neurosci"},{"key":"1675_CR11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0959-4388(00)00215-4","volume":"11","author":"S Cull-Candy","year":"2001","unstructured":"Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Current Opin Neurobiol. 2001;11:327\u201335.","journal-title":"Current Opin Neurobiol"},{"key":"1675_CR12","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.neuron.2023.05.002","volume":"111","author":"JP Dupuis","year":"2023","unstructured":"Dupuis JP, Nicole O, Groc L. NMDA receptor functions in health and disease: old actor, new dimensions. Neuron. 2023;111:2312\u201328.","journal-title":"Neuron."},{"key":"1675_CR13","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.tips.2011.08.003","volume":"32","author":"KK Ogden","year":"2011","unstructured":"Ogden KK, Traynelis SF. New advances in NMDA receptor pharmacology. Trends Pharmacol Sci. 2011;32:726\u201333.","journal-title":"Trends Pharmacol Sci"},{"key":"1675_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2004.05.005","volume":"51","author":"SK Sonkusare","year":"2005","unstructured":"Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer\u2019s disease and other neurodegenerative disorders\u2014memantine, a new hope. Pharmacol Res. 2005;51:1\u201317.","journal-title":"Pharmacol Res"},{"key":"1675_CR15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40263-022-00968-4","volume":"36","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Dextromethorphan\/Bupropion: first approval. CNS Drugs. 2022;36:1229\u201338.","journal-title":"CNS Drugs"},{"key":"1675_CR16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","volume":"73","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73:613\u201327.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1675_CR17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/13543776.2020.1811234","volume":"30","author":"H Ahmed","year":"2020","unstructured":"Ahmed H, Haider A, Ametamey SM. N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present). Expert Opin Ther Pat. 2020;30:743\u201367.","journal-title":"Expert Opin Ther Pat"},{"key":"1675_CR18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1517\/13543776.2014.972938","volume":"24","author":"KL Strong","year":"2014","unstructured":"Strong KL, Jing Y, Prosser AR, Traynelis SF, Liotta DC. NMDA receptor modulators: an updated patent review (2013 \u2013 2014). Expert Opin Ther Pat. 2014;24:1349\u201366.","journal-title":"Expert Opin Ther Pat"},{"key":"1675_CR19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/0006-291X(92)91701-Q","volume":"185","author":"H Sugihara","year":"1992","unstructured":"Sugihara H, Moriyoshi K, Ishii T, Masu M, Nakanishi S. Structures and properties of seven isoforms of the NMDA receptor generated by alternative splicing. Biochem Biophys Res Commun. 1992;185:826\u201332.","journal-title":"Biochem Biophys Res Commun"},{"key":"1675_CR20","doi-asserted-by":"crossref","first-page":"9683","DOI":"10.1074\/jbc.M807050200","volume":"284","author":"M Horak","year":"2009","unstructured":"Horak M, Wenthold RJ. Different roles of C-terminal cassettes in the trafficking of full-length NR1 subunits to the cell surface. J Biol Chem. 2009;284:9683\u201391.","journal-title":"J Biol Chem"},{"key":"1675_CR21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/354031a0","volume":"354","author":"K Moriyoshi","year":"1991","unstructured":"Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature. 1991;354:31\u20137.","journal-title":"Nature."},{"key":"1675_CR22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0165-3806(02)00572-2","volume":"139","author":"LM Ritter","year":"2002","unstructured":"Ritter LM, Vazquez DM, Meador-Woodruff JH. Ontogeny of ionotropic glutamate receptor subunit expression in the rat hippocampus. Brain Res Dev Brain Res. 2002;139:227\u201336.","journal-title":"Brain Res Dev Brain Res"},{"key":"1675_CR23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0896-6273(94)90210-0","volume":"12","author":"H Monyer","year":"1994","unstructured":"Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 1994;12:529\u201340.","journal-title":"Neuron."},{"key":"1675_CR24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1097\/00001756-199212000-00027","volume":"3","author":"M Watanabe","year":"1992","unstructured":"Watanabe M, Inoue Y, Sakimura K, Mishina M. Developmental changes in distribution of NMDA receptor channel subunit mRNAs. Neuroreport. 1992;3:1138\u201340.","journal-title":"Neuroreport."},{"key":"1675_CR25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/cne.903470112","volume":"347","author":"C Akazawa","year":"1994","unstructured":"Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, Mizuno N. Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol. 1994;347:150\u201360.","journal-title":"J Comp Neurol"},{"key":"1675_CR26","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/cercor\/bhaa330","volume":"31","author":"A Murillo","year":"2021","unstructured":"Murillo A, Navarro AI, Puelles E, Zhang Y, Petros TJ, P\u00e9rez-Ota\u00f1o I. Temporal dynamics and neuronal specificity of Grin3a expression in the mouse forebrain. Cereb Cortex. 2021;31:1914\u201326.","journal-title":"Cereb Cortex"},{"key":"1675_CR27","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1523\/JNEUROSCI.15-10-06509.1995","volume":"15","author":"NJ Sucher","year":"1995","unstructured":"Sucher NJ, Akbarian S, Chi CL, Leclerc CL, Awobuluyi M, Deitcher DL, et al. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J Neurosci. 1995;15:6509\u201320.","journal-title":"J Neurosci"},{"key":"1675_CR28","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1523\/JNEUROSCI.15-10-06498.1995","volume":"15","author":"AM Ciabarra","year":"1995","unstructured":"Ciabarra AM, Sullivan JM, Gahn LG, Pecht G, Heinemann S, Sevarino KA. Cloning and characterization of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J Neurosci. 1995;15:6498\u2013508.","journal-title":"J Neurosci"},{"key":"1675_CR29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cne.10314","volume":"450","author":"HK Wong","year":"2002","unstructured":"Wong HK, Liu XB, Matos MF, Chan SF, P\u00e9rez-Ota\u00f1o I, Boysen M, et al. Temporal and regional expression of NMDA receptor subunit NR3A in the mammalian brain. J Comp Neurol. 2002;450:303\u201317.","journal-title":"J Comp Neurol"},{"key":"1675_CR30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cne.21747","volume":"509","author":"KSL Wee","year":"2008","unstructured":"Wee KSL, Zhang Y, Khanna S, Low CM. Immunolocalization of NMDA receptor subunit NR3B in selected structures in the rat forebrain, cerebellum, and lumbar spinal cord. J Comp Neurol. 2008;509:118\u201335.","journal-title":"J Comp Neurol"},{"key":"1675_CR31","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1460-9568.2005.03957.x","volume":"21","author":"M Fukaya","year":"2005","unstructured":"Fukaya M, Hayashi Y, Watanabe M. NR2 to NR3B subunit switchover of NMDA receptors in early postnatal motoneurons. Eur J Neurosci. 2005;21:1432\u20136.","journal-title":"Eur J Neurosci"},{"key":"1675_CR32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0169-328X(02)00173-0","volume":"100","author":"K Matsuda","year":"2002","unstructured":"Matsuda K, Kamiya Y, Matsuda S, Yuzaki M. Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability. Brain Res Mol Brain Res. 2002;100:43\u201352.","journal-title":"Brain Res Mol Brain Res"},{"key":"1675_CR33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0014-5793(98)01590-7","volume":"441","author":"L Sun","year":"1998","unstructured":"Sun L, Margolis FL, Shipley MT, Lidow MS. Identification of a long variant of mRNA encoding the NR3 subunit of the NMDA receptor: its regional distribution and developmental expression in the rat brain. FEBS Lett. 1998;441:392\u20136.","journal-title":"FEBS Lett"},{"key":"1675_CR34","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.256.5060.1217","volume":"256","author":"H Monyer","year":"1992","unstructured":"Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, et al. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science. 1992;256:1217\u201321.","journal-title":"Science."},{"key":"1675_CR35","doi-asserted-by":"crossref","first-page":"14163","DOI":"10.1073\/pnas.0802075105","volume":"105","author":"MH Ulbrich","year":"2008","unstructured":"Ulbrich MH, Isacoff EY. Rules of engagement for NMDA receptor subunits. Proc Natl Acad Sci USA. 2008;105:14163\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1675_CR36","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.neuron.2014.01.035","volume":"81","author":"KB Hansen","year":"2014","unstructured":"Hansen KB, Ogden KK, Yuan H, Traynelis SF. Distinct functional and pharmacological properties of Triheteromeric GluN1\/GluN2A\/GluN2B NMDA receptors. Neuron. 2014;81:1084\u201396.","journal-title":"Neuron."},{"key":"1675_CR37","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1074\/jbc.M110.182600","volume":"286","author":"C Rauner","year":"2011","unstructured":"Rauner C, K\u00f6hr G. Triheteromeric NR1\/NR2A\/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses. J Biol Chem. 2011;286:7558\u201366.","journal-title":"J Biol Chem"},{"key":"1675_CR38","doi-asserted-by":"crossref","first-page":"8334","DOI":"10.1523\/JNEUROSCI.2155-07.2007","volume":"27","author":"RA Al-Hallaq","year":"2007","unstructured":"Al-Hallaq RA, Conrads TP, Veenstra TD, Wenthold RJ. NMDA di-heteromeric receptor populations and associated proteins in rat hippocampus. J Neurosci. 2007;27:8334\u201343.","journal-title":"J Neurosci"},{"key":"1675_CR39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1126\/science.1251915","volume":"344","author":"E Karakas","year":"2014","unstructured":"Karakas E, Furukawa H. Crystal structure of a heterotetrameric NMDA receptor ion channel. Science. 2014;344:992\u20137.","journal-title":"Science."},{"key":"1675_CR40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature13548","volume":"511","author":"CH Lee","year":"2014","unstructured":"Lee CH, L\u00fc W, Michel JC, Goehring A, Du J, Song X, et al. NMDA receptor structures reveal subunit arrangement and pore architecture. Nature. 2014;511:191\u20137.","journal-title":"Nature."},{"key":"1675_CR41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0166-2236(96)80019-1","volume":"19","author":"P K\u00f6nig","year":"1996","unstructured":"K\u00f6nig P, Engel AK, Singer W. Integrator or coincidence detector? The role of the cortical neuron revisited. Trends Neurosci. 1996;19:130\u20137.","journal-title":"Trends Neurosci"},{"key":"1675_CR42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nature715","volume":"415","author":"JE Chatterton","year":"2002","unstructured":"Chatterton JE, Awobuluyi M, Premkumar LS, Takahashi H, Talantova M, Shin Y, et al. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature. 2002;415:793\u20138.","journal-title":"Nature."},{"key":"1675_CR43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1124\/jpet.107.123836","volume":"322","author":"CT Smothers","year":"2007","unstructured":"Smothers CT, Woodward JJ. Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits. J Pharmacol Exp Ther. 2007;322:739\u201348.","journal-title":"J Pharmacol Exp Ther"},{"key":"1675_CR44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrn.2016.92","volume":"17","author":"I P\u00e9rez-Ota\u00f1o","year":"2016","unstructured":"P\u00e9rez-Ota\u00f1o I, Larsen RS, Wesseling JF. Emerging roles of GluN3-containing NMDA receptors in the CNS. Nat Rev Neurosci. 2016;17:623\u201335.","journal-title":"Nat Rev Neurosci"},{"key":"1675_CR45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1126\/science.aax1522","volume":"366","author":"Y Otsu","year":"2019","unstructured":"Otsu Y, Darcq E, Pietrajtis K, M\u00e1ty\u00e1s F, Schwartz E, Bessaih T, et al. Control of aversion by glycine-gated GluN1\/GluN3A NMDA receptors in the adult medial habenula. Science. 2019;366:250\u20134.","journal-title":"Science."},{"key":"1675_CR46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.tins.2023.05.002","volume":"46","author":"S Bossi","year":"2023","unstructured":"Bossi S, Pizzamiglio L, Paoletti P. Excitatory GluN1\/GluN3A glycine receptors (eGlyRs) in brain signaling. Trends Neurosci. 2023;46:667\u201381.","journal-title":"Trends Neurosci"},{"key":"1675_CR47","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.neuron.2022.05.016","volume":"110","author":"S Bossi","year":"2022","unstructured":"Bossi S, Dhanasobhon D, Ellis-Davies GCR, Frontera J, de Brito Van Velze M, Louren\u00e7o J, et al. GluN3A excitatory glycine receptors control adult cortical and amygdalar circuits. Neuron. 2022;110:2438\u201354.e8.","journal-title":"Neuron."},{"key":"1675_CR48","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07236-4","volume":"9","author":"T Grand","year":"2018","unstructured":"Grand T, Abi Gerges S, David M, Diana MA, Paoletti P. Unmasking GluN1\/GluN3A excitatory glycine NMDA receptors. Nat Commun. 2018;9:4769.","journal-title":"Nat Commun"},{"key":"1675_CR49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/368144a0","volume":"368","author":"M Sheng","year":"1994","unstructured":"Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature. 1994;368:144\u20137.","journal-title":"Nature."},{"key":"1675_CR50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.neuron.2005.08.034","volume":"48","author":"A Barria","year":"2005","unstructured":"Barria A, Malinow R. NMDA receptor subunit composition controls synaptic plasticity by regulating binding to CaMKII. Neuron. 2005;48:289\u2013301.","journal-title":"Neuron."},{"key":"1675_CR51","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.cell.2025.01.004","volume":"188","author":"M Zhang","year":"2025","unstructured":"Zhang M, Feng J, Xie C, Song N, Jin C, Wang J, et al. Assembly and architecture of endogenous NMDA receptors in adult cerebral cortex and hippocampus. Cell. 2025;188:1198\u2013207.e13.","journal-title":"Cell."},{"key":"1675_CR52","doi-asserted-by":"crossref","first-page":"16630","DOI":"10.1523\/JNEUROSCI.2736-14.2014","volume":"34","author":"D Stroebel","year":"2014","unstructured":"Stroebel D, Carvalho S, Grand T, Zhu S, Paoletti P. Controlling NMDA receptor subunit composition using ectopic retention signals. J Neurosci. 2014;34:16630\u20136.","journal-title":"J Neurosci"},{"key":"1675_CR53","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1523\/JNEUROSCI.0829-13.2013","volume":"33","author":"KR Tovar","year":"2013","unstructured":"Tovar KR, McGinley MJ, Westbrook GL. Triheteromeric NMDA receptors at hippocampal synapses. J Neurosci. 2013;33:9150\u201360.","journal-title":"J Neurosci"},{"key":"1675_CR54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1113\/jphysiol.1996.sp021779","volume":"497","author":"ED Kirson","year":"1996","unstructured":"Kirson ED, Yaari Y. Synaptic NMDA receptors in developing mouse hippocampal neurones: functional properties and sensitivity to ifenprodil. J Physiol. 1996;497:437\u201355.","journal-title":"J Physiol"},{"key":"1675_CR55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","volume":"37","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37:4\u201315.","journal-title":"Neuropsychopharmacology."},{"key":"1675_CR56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archpsyc.61.7.649","volume":"61","author":"TUW Woo","year":"2004","unstructured":"Woo TUW, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry. 2004;61:649\u201357.","journal-title":"Arch Gen Psychiatry"},{"key":"1675_CR57","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.schres.2004.02.016","volume":"71","author":"HT Mueller","year":"2004","unstructured":"Mueller HT, Meador-Woodruff JH. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr Res. 2004;71:361\u201370.","journal-title":"Schizophr Res"},{"key":"1675_CR58","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1523\/JNEUROSCI.4722-05.2006","volume":"26","author":"JW Kinney","year":"2006","unstructured":"Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci. 2006;26:1604\u201315.","journal-title":"J Neurosci"},{"key":"1675_CR59","doi-asserted-by":"crossref","first-page":"107426","DOI":"10.1016\/j.pharmthera.2019.107426","volume":"205","author":"K Nakazawa","year":"2020","unstructured":"Nakazawa K, Sapkota K. The origin of NMDA receptor hypofunction in schizophrenia. Pharmacol Ther. 2020;205:107426.","journal-title":"Pharmacol Ther"},{"key":"1675_CR60","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1523\/JNEUROSCI.1014-09.2009","volume":"29","author":"Z Xu","year":"2009","unstructured":"Xu Z, Chen RQ, Gu QH, Yan JZ, Wang SH, Liu SY, et al. Metaplastic regulation of long-term potentiation\/long-term depression threshold by activity-dependent changes of NR2A\/NR2B ratio. J Neurosci. 2009;29:8764\u201373.","journal-title":"J Neurosci"},{"key":"1675_CR61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1750-1326-6-68","volume":"6","author":"A Jullienne","year":"2011","unstructured":"Jullienne A, Montagne A, Orset C, Lesept F, Jane DE, Monaghan DT, et al. Selective inhibition of GluN2D-containing N-methyl-D-aspartate receptors prevents tissue plasminogen activator-promoted neurotoxicity both in vitro and in vivo. Mol Neurodegener. 2011;6:68.","journal-title":"Mol Neurodegener"},{"key":"1675_CR62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nn835","volume":"5","author":"GE Hardingham","year":"2002","unstructured":"Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405\u201314.","journal-title":"Nat Neurosci"},{"key":"1675_CR63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13024-023-00636-1","volume":"18","author":"SP Yu","year":"2023","unstructured":"Yu SP, Jiang MQ, Shim SS, Pourkhodadad S, Wei L. Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer\u2019s disease. Mol Neurodegener. 2023;18:43.","journal-title":"Mol Neurodegener"},{"key":"1675_CR64","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1007\/s12035-017-0395-8","volume":"55","author":"Y Sun","year":"2018","unstructured":"Sun Y, Cheng X, Hu J, Gao Z. The role of GluN2A in cerebral ischemia: promoting neuron death and survival in the early stage and thereafter. Mol Neurobiol. 2018;55:1208\u201316.","journal-title":"Mol Neurobiol"},{"key":"1675_CR65","first-page":"211","volume":"4","author":"B Lujan","year":"2012","unstructured":"Lujan B, Liu X, Wan Q. Differential roles of GluN2A- and GluN2B-containing NMDA receptors in neuronal survival and death. Int J Physiol Pathophysiol Pharmacol. 2012;4:211\u20138.","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"1675_CR66","volume":"6","author":"R Hu","year":"2016","unstructured":"Hu R, Chen J, Lujan B, Lei R, Zhang M, Wang Z, et al. Glycine triggers a non-ionotropic activity of GluN2A-containing NMDA receptors to confer neuroprotection. Sci Rep. 2016;6:34459.","journal-title":"Sci Rep"},{"key":"1675_CR67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuropharm.2007.04.015","volume":"53","author":"J von Engelhardt","year":"2007","unstructured":"von Engelhardt J, Coserea I, Pawlak V, Fuchs EC, K\u00f6hr G, Seeburg PH, et al. Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. Neuropharmacology. 2007;53:10\u20137.","journal-title":"Neuropharmacology."},{"key":"1675_CR68","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1523\/JNEUROSCI.0116-07.2007","volume":"27","author":"Y Liu","year":"2007","unstructured":"Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci. 2007;27:2846\u201357.","journal-title":"J Neurosci"},{"key":"1675_CR69","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nn1503","volume":"8","author":"EM Snyder","year":"2005","unstructured":"Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051\u20138.","journal-title":"Nat Neurosci"},{"key":"1675_CR70","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1016\/j.celrep.2018.05.036","volume":"23","author":"P Opazo","year":"2018","unstructured":"Opazo P, Viana da Silva S, Carta M, Breillat C, Coultrap SJ, Grillo-Bosch D, et al. CaMKII metaplasticity drives A\u03b2 oligomer-mediated synaptotoxicity. Cell Rep. 2018;23:3137\u201345.","journal-title":"Cell Rep"},{"key":"1675_CR71","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","volume":"142","author":"LM Ittner","year":"2010","unstructured":"Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer\u2019s disease mouse models. Cell. 2010;142:387\u201397.","journal-title":"Cell."},{"key":"1675_CR72","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coph.2014.12.004","volume":"20","author":"DT Balu","year":"2015","unstructured":"Balu DT, Coyle JT. The NMDA receptor \u2018glycine modulatory site\u2019 in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol. 2015;20:109\u201315.","journal-title":"Curr Opin Pharmacol"},{"key":"1675_CR73","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.neubiorev.2009.08.002","volume":"34","author":"V Labrie","year":"2010","unstructured":"Labrie V, Roder JC. The involvement of the NMDA receptor D-serine\/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev. 2010;34:351\u201372.","journal-title":"Neurosci Biobehav Rev"},{"key":"1675_CR74","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","volume":"174","author":"JT Coyle","year":"2004","unstructured":"Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl). 2004;174:32\u20138.","journal-title":"Psychopharmacology (Berl)"},{"key":"1675_CR75","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1126\/science.1072873","volume":"298","author":"M Aarts","year":"2002","unstructured":"Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science. 2002;298:846\u201350.","journal-title":"Science."},{"key":"1675_CR76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pneurobio.2013.11.006","volume":"115","author":"TW Lai","year":"2014","unstructured":"Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol. 2014;115:157\u201388.","journal-title":"Prog Neurobiol"},{"key":"1675_CR77","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/1567205053585846","volume":"2","author":"SA Lipton","year":"2005","unstructured":"Lipton SA. The molecular basis of memantine action in Alzheimer\u2019s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res. 2005;2:155\u201365.","journal-title":"Curr Alzheimer Res"},{"key":"1675_CR78","unstructured":"Organization WH. Global Health Estimates: Depression and Other Common Mental Disorders. 2017 [cited 2025 Jun 17]; Available from: https:\/\/policycommons.net\/artifacts\/546082\/depression-and-other-common-mental-disorders\/1523689\/"},{"key":"1675_CR79","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)02141-3","volume":"399","author":"H Herrman","year":"2022","unstructured":"Herrman H, Patel V, Kieling C, Berk M, Buchweitz C, Cuijpers P, et al. Time for united action on depression: a Lancet-World Psychiatric Association Commission. Lancet. 2022;399:957\u20131022.","journal-title":"Lancet."},{"key":"1675_CR80","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(22)02080-3","volume":"401","author":"S Marwaha","year":"2023","unstructured":"Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. Lancet. 2023;401:141\u201353.","journal-title":"Lancet."},{"key":"1675_CR81","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","volume":"392","author":"GS Malhi","year":"2018","unstructured":"Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299\u2013312.","journal-title":"Lancet."},{"key":"1675_CR82","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00702-013-1130-x","volume":"121","author":"MJ Niciu","year":"2014","unstructured":"Niciu MJ, Ionescu DF, Richards EM, Zarate CA. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna). 2014;121:907\u201324.","journal-title":"J Neural Transm (Vienna)"},{"key":"1675_CR83","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41392-024-01738-y","volume":"9","author":"L Cui","year":"2024","unstructured":"Cui L, Li S, Wang S, Wu X, Liu Y, Yu W, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther. 2024;9:30.","journal-title":"Signal Transduct Target Ther"},{"key":"1675_CR84","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1085\/jgp.201812032","volume":"150","author":"KB Hansen","year":"2018","unstructured":"Hansen KB, Yi F, Perszyk RE, Furukawa H, Wollmuth LP, Gibb AJ, et al. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018;150:1081\u2013105.","journal-title":"J Gen Physiol"},{"key":"1675_CR85","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1113\/jphysiol.1995.sp020591","volume":"483","author":"M Benveniste","year":"1995","unstructured":"Benveniste M, Mayer ML. Trapping of glutamate and glycine during open channel block of rat hippocampal neuron NMDA receptors by 9-aminoacridine. J Physiol. 1995;483:367\u201384.","journal-title":"J Physiol"},{"key":"1675_CR86","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0005-2736(98)00211-9","volume":"1416","author":"AI Sobolevsky","year":"1999","unstructured":"Sobolevsky AI. Two-component blocking kinetics of open NMDA channels by organic cations. Biochim Biophys Acta. 1999;1416:69\u201391.","journal-title":"Biochim Biophys Acta"},{"key":"1675_CR87","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.neuropharm.2018.08.010","volume":"140","author":"M Kaniakova","year":"2018","unstructured":"Kaniakova M, Kleteckova L, Lichnerova K, Holubova K, Skrenkova K, Korinek M, et al. 7-Methoxyderivative of tacrine is a \u2018foot-in-the-door\u2019 open-channel blocker of GluN1\/GluN2 and GluN1\/GluN3 NMDA receptors with neuroprotective activity in vivo. Neuropharmacology. 2018;140:217\u201332.","journal-title":"Neuropharmacology."},{"key":"1675_CR88","doi-asserted-by":"crossref","first-page":"10611","DOI":"10.1523\/JNEUROSCI.19-24-10611.1999","volume":"19","author":"AI Sobolevsky","year":"1999","unstructured":"Sobolevsky AI, Koshelev SG, Khodorov BI. Probing of NMDA channels with fast blockers. J Neurosci. 1999;19:10611\u201326.","journal-title":"J Neurosci"},{"key":"1675_CR89","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.neuron.2021.05.031","volume":"109","author":"H Wang","year":"2021","unstructured":"Wang H, Lv S, Stroebel D, Zhang J, Pan Y, Huang X, et al. Gating mechanism and a modulatory niche of human GluN1-GluN2A NMDA receptors. Neuron. 2021;109:2443\u201356.e5.","journal-title":"Neuron."},{"key":"1675_CR90","doi-asserted-by":"crossref","first-page":"174795","DOI":"10.1016\/j.ejphar.2022.174795","volume":"919","author":"AS Zhigulin","year":"2022","unstructured":"Zhigulin AS, Barygin OI. Mechanisms of NMDA receptor inhibition by nafamostat, gabexate and furamidine. Eur J Pharmacol. 2022;919:174795.","journal-title":"Eur J Pharmacol"},{"key":"1675_CR91","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1471-4159.2003.01956.x","volume":"87","author":"KV Bolshakov","year":"2003","unstructured":"Bolshakov KV, Gmiro VE, Tikhonov DB, Magazanik LG. Determinants of trapping block of N-methyl-D-aspartate receptor channels. J Neurochem. 2003;87:56\u201365.","journal-title":"J Neurochem"},{"key":"1675_CR92","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1152\/jn.1997.77.1.309","volume":"77","author":"TA Blanpied","year":"1997","unstructured":"Blanpied TA, Boeckman FA, Aizenman E, Johnson JW. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol. 1997;77:309\u201323.","journal-title":"J Neurophysiol"},{"key":"1675_CR93","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0022-3565(24)37943-1","volume":"288","author":"GA Mealing","year":"1999","unstructured":"Mealing GA, Lanthorn TH, Murray CL, Small DL, Morley P. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Ther. 1999;288:204\u201310.","journal-title":"J Pharmacol Exp Ther"},{"key":"1675_CR94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1113\/jphysiol.1997.sp021909","volume":"499","author":"HS Chen","year":"1997","unstructured":"Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol. 1997;499:27\u201346.","journal-title":"J Physiol"},{"key":"1675_CR95","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1113\/jphysiol.2009.176297","volume":"587","author":"SE Kotermanski","year":"2009","unstructured":"Kotermanski SE, Wood JT, Johnson JW. Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J Physiol. 2009;587:4589\u2013604.","journal-title":"J Physiol"},{"key":"1675_CR96","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1113\/jphysiol.2006.124958","volume":"581","author":"SM Dravid","year":"2007","unstructured":"Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, et al. Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol. 2007;581:107\u201328.","journal-title":"J Physiol"},{"key":"1675_CR97","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1469-7793.2000.t01-2-00493.x","volume":"526","author":"AI Sobolevsky","year":"2000","unstructured":"Sobolevsky AI, Yelshansky MV. The trapping block of NMDA receptor channels in acutely isolated rat hippocampal neurones. J Physiol. 2000;526:493\u2013506.","journal-title":"J Physiol"},{"key":"1675_CR98","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0006-3495(98)77622-2","volume":"75","author":"JG Dilmore","year":"1998","unstructured":"Dilmore JG, Johnson JW. Open channel block and alteration of N-methyl-D-aspartic acid receptor gating by an analog of phencyclidine. Biophys J. 1998;75:1801\u201316.","journal-title":"Biophys J"},{"key":"1675_CR99","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"1675_CR100","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"1675_CR101","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","volume":"74","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74:250\u20136.","journal-title":"Biol Psychiatry"},{"key":"1675_CR102","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-020-00897-0","volume":"10","author":"PR Shiroma","year":"2020","unstructured":"Shiroma PR, Thuras P, Wels J, Albott CS, Erbes C, Tye S, et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry. 2020;10:206.","journal-title":"Transl Psychiatry"},{"key":"1675_CR103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","volume":"67","author":"M Rot","year":"2010","unstructured":"Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139\u201345. aan het","journal-title":"Biol Psychiatry"},{"key":"1675_CR104","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.biopsych.2012.03.029","volume":"72","author":"BR Cornwell","year":"2012","unstructured":"Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry. 2012;72:555\u201361.","journal-title":"Biol Psychiatry"},{"key":"1675_CR105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881114527361","volume":"28","author":"PR Diamond","year":"2014","unstructured":"Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28:536\u201344.","journal-title":"J Psychopharmacol"},{"key":"1675_CR106","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76:893\u2013903.","journal-title":"JAMA Psychiatry"},{"key":"1675_CR107","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75:139\u201348.","journal-title":"JAMA Psychiatry"},{"key":"1675_CR108","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176:428\u201338.","journal-title":"Am J Psychiatry"},{"key":"1675_CR109","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","volume":"338","author":"RS Duman","year":"2012","unstructured":"Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338:68\u201372.","journal-title":"Science."},{"key":"1675_CR110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-pharmtox-011613-135950","volume":"54","author":"MJ Niciu","year":"2014","unstructured":"Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA, Charney DS. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol. 2014;54:119\u201339.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1675_CR111","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","volume":"172","author":"DJ Newport","year":"2015","unstructured":"Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172:950\u201366.","journal-title":"Am J Psychiatry"},{"key":"1675_CR112","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.biopsych.2016.05.005","volume":"81","author":"MS Lener","year":"2017","unstructured":"Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry. 2017;81:886\u201397.","journal-title":"Biol Psychiatry"},{"key":"1675_CR113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","volume":"102","author":"RS Duman","year":"2019","unstructured":"Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102:75\u201390.","journal-title":"Neuron."},{"key":"1675_CR114","doi-asserted-by":"crossref","first-page":"109378","DOI":"10.1016\/j.neuropharm.2022.109378","volume":"225","author":"S Lv","year":"2023","unstructured":"Lv S, Yao K, Zhang Y, Zhu S. NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research. Neuropharmacology. 2023;225:109378.","journal-title":"Neuropharmacology."},{"key":"1675_CR115","doi-asserted-by":"crossref","first-page":"E3007","DOI":"10.1073\/pnas.1718883115","volume":"115","author":"AJ Widman","year":"2018","unstructured":"Widman AJ, McMahon LL. Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. Proc Natl Acad Sci USA. 2018;115:E3007\u201316.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1675_CR116","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1126\/science.1835799","volume":"254","author":"JW Olney","year":"1991","unstructured":"Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254:1515\u20138.","journal-title":"Science"},{"key":"1675_CR117","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1038\/s41380-020-0796-3","volume":"26","author":"S Pothula","year":"2021","unstructured":"Pothula S, Kato T, Liu RJ, Wu M, Gerhard D, Shinohara R, et al. Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Mol Psychiatry. 2021;26:5097\u2013111.","journal-title":"Mol Psychiatry"},{"key":"1675_CR118","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1172\/JCI130808","volume":"130","author":"DM Gerhard","year":"2020","unstructured":"Gerhard DM, Pothula S, Liu RJ, Wu M, Li XY, Girgenti MJ, et al. GABA interneurons are the cellular trigger for ketamine\u2019s rapid antidepressant actions. J Clin Invest. 2020;130:1336\u201349.","journal-title":"J Clin Invest"},{"key":"1675_CR119","doi-asserted-by":"crossref","first-page":"eaat8078","DOI":"10.1126\/science.aat8078","volume":"364","author":"RN Moda-Sava","year":"2019","unstructured":"Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364:eaat8078.","journal-title":"Science"},{"key":"1675_CR120","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959\u201364.","journal-title":"Science."},{"key":"1675_CR121","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Pfei C, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91\u20135.","journal-title":"Nature."},{"key":"1675_CR122","doi-asserted-by":"crossref","first-page":"e09262","DOI":"10.7554\/eLife.09262","volume":"4","author":"AL Reese","year":"2015","unstructured":"Reese AL, Kavalali ET. Spontaneous neurotransmission signals through store-driven Ca2+ transients to maintain synaptic homeostasis. Elife. 2015;4:e09262.","journal-title":"Elife."},{"key":"1675_CR123","doi-asserted-by":"crossref","first-page":"e03581","DOI":"10.7554\/eLife.03581","volume":"3","author":"OH Miller","year":"2014","unstructured":"Miller OH, Yang L, Wang CC, Hargroder EA, Zhang Y, Delpire E, et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife. 2014;3:e03581.","journal-title":"Elife"},{"key":"1675_CR124","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature25509","volume":"554","author":"Y Yang","year":"2018","unstructured":"Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554:317\u201322.","journal-title":"Nature."},{"key":"1675_CR125","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41586-023-06624-1","volume":"622","author":"S Ma","year":"2023","unstructured":"Ma S, Chen M, Jiang Y, Xiang X, Wang S, Wu Z, et al. Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb. Nature. 2023;622:802\u20139.","journal-title":"Nature."},{"key":"1675_CR126","doi-asserted-by":"crossref","first-page":"eado7010","DOI":"10.1126\/science.ado7010","volume":"385","author":"M Chen","year":"2024","unstructured":"Chen M, Ma S, Liu H, Dong Y, Tang J, Ni Z, et al. Brain region-specific action of ketamine as a rapid antidepressant. Science. 2024;385:eado7010.","journal-title":"Science."},{"key":"1675_CR127","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-021-03769-9","volume":"596","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Ye F, Zhang T, Lv S, Zhou L, Du D, et al. Structural basis of ketamine action on human NMDA receptors. Nature. 2021;596:301\u20135.","journal-title":"Nature."},{"key":"1675_CR128","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/0028-3908(95)00092-K","volume":"34","author":"CG Parsons","year":"1995","unstructured":"Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology. 1995;34:1239\u201358.","journal-title":"Neuropharmacology."},{"key":"1675_CR129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14728214.2021.1898588","volume":"26","author":"A Majeed","year":"2021","unstructured":"Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. Expert Opin Emerg Drugs. 2021;26:63\u201374.","journal-title":"Expert Opin Emerg Drugs"},{"key":"1675_CR130","doi-asserted-by":"crossref","first-page":"e89985","DOI":"10.1371\/journal.pone.0089985","volume":"9","author":"L Nguyen","year":"2014","unstructured":"Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One. 2014;9:e89985.","journal-title":"PLoS One"},{"key":"1675_CR131","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/WNR.0000000000000646","volume":"27","author":"L Nguyen","year":"2016","unstructured":"Nguyen L, Lucke-Wold BP, Logsdon AF, Scandinaro AL, Huber JD, Matsumoto RR. Behavioral and biochemical effects of ketamine and dextromethorphan relative to its antidepressant-like effects in Swiss Webster mice. Neuroreport. 2016;27:1004\u201311.","journal-title":"Neuroreport."},{"key":"1675_CR132","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopha.2016.11.073","volume":"85","author":"E Sakhaee","year":"2017","unstructured":"Sakhaee E, Ostadhadi S, Khan MI, Yousefi F, Norouzi-Javidan A, Akbarian R, et al. The role of NMDA receptor and nitric oxide\/cyclic guanosine monophosphate pathway in the antidepressant-like effect of dextromethorphan in mice forced swimming test and tail suspension test. Biomed Pharmacother. 2017;85:627\u201334.","journal-title":"Biomed Pharmacother"},{"key":"1675_CR133","doi-asserted-by":"crossref","first-page":"173003","DOI":"10.1016\/j.pbb.2020.173003","volume":"197","author":"JS Saavedra","year":"2020","unstructured":"Saavedra JS, Garrett PI, Honeycutt SC, Peterson AM, White JW, Hillhouse TM. Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice. Pharmacol Biochem Behav. 2020;197:173003.","journal-title":"Pharmacol Biochem Behav"},{"key":"1675_CR134","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2015.03.024","volume":"295","author":"L Nguyen","year":"2015","unstructured":"Nguyen L, Matsumoto RR. Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. Behav Brain Res. 2015;295:26\u201334.","journal-title":"Behav Brain Res"},{"key":"1675_CR135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.9758\/cpn.23.1081","volume":"21","author":"B McCarthy","year":"2023","unstructured":"McCarthy B, Bunn H, Santalucia M, Wilmouth C, Muzyk A, Smith CM. Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder. Clin Psychopharmacol Neurosci. 2023;21:609\u201316.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"1675_CR136","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","volume":"179","author":"H Tabuteau","year":"2022","unstructured":"Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS-05 (Dextromethorphan-Bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022;179:490\u20139.","journal-title":"Am J Psychiatry"},{"key":"1675_CR137","first-page":"21m14345","volume":"83","author":"DV Iosifescu","year":"2022","unstructured":"Iosifescu DV, Jones A, O\u2019Gorman C, Streicher C, Feliz S, Fava M, et al. Efficacy and safety of AXS-05 (Dextromethorphan-Bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry. 2022;83:21m14345.","journal-title":"J Clin Psychiatry"},{"key":"1675_CR138","unstructured":"Side Effects - AUVELITY (dextromethorphan-bupropion) [Internet]. [cited 2025 Jun 27]. Available from: https:\/\/www.auvelity.com\/side-effects"},{"key":"1675_CR139","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/ph15080997","volume":"15","author":"E Bettini","year":"2022","unstructured":"Bettini E, Stahl SM, De Martin S, Mattarei A, Sgrignani J, Carignani C, et al. Pharmacological comparative characterization of REL-1017 (Esmethadone-HCl) and other NMDAR channel blockers in human heterodimeric N-methyl-D-aspartate receptors. Pharmaceuticals (Basel). 2022;15:997.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1675_CR140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(97)13391-2","volume":"223","author":"AL Gorman","year":"1997","unstructured":"Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 1997;223:5\u20138.","journal-title":"Neurosci Lett"},{"key":"1675_CR141","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15055-3","volume":"12","author":"J Henningfield","year":"2022","unstructured":"Henningfield J, Gauvin D, Bifari F, Fant R, Shram M, Buchhalter A, et al. REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats. Sci Rep. 2022;12:11389.","journal-title":"Sci Rep"},{"key":"1675_CR142","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-023-02473-8","volume":"13","author":"MJ Shram","year":"2023","unstructured":"Shram MJ, Henningfield JE, Apseloff G, Gorodetzky CW, De Martin S, Vocci FL, et al. The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users. Transl Psychiatry. 2023;13:192.","journal-title":"Transl Psychiatry"},{"key":"1675_CR143","first-page":"24m15438","volume":"86","author":"M Fava","year":"2025","unstructured":"Fava M, Pani L, De Martin S, Cutler AJ, Gorodetzky CW, Vocci FJ, et al. Long-term safety and efficacy of esmethadone in patients with major depressive disorder: findings from a 12-month open-label study. J Clin Psychiatry. 2025;86:24m15438.","journal-title":"J Clin Psychiatry"},{"key":"1675_CR144","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCP.0000000000001035","volume":"39","author":"G Bernstein","year":"2019","unstructured":"Bernstein G, Davis K, Mills C, Wang L, McDonnell M, Oldenhof J, et al. Characterization of the safety and pharmacokinetic profile of D-methadone, a novel N-methyl-D-aspartate receptor antagonist in healthy, opioid-naive subjects: results of two phase 1 studies. J Clin Psychopharmacol. 2019;39:226\u201337.","journal-title":"J Clin Psychopharmacol"},{"key":"1675_CR145","doi-asserted-by":"crossref","first-page":"671859","DOI":"10.3389\/fphar.2021.671859","volume":"12","author":"S De Martin","year":"2021","unstructured":"De Martin S, Gabbia D, Folli F, Bifari F, Fiorina P, Ferri N, et al. REL-1017 (Esmethadone) increases circulating BDNF levels in healthy subjects of a phase 1 clinical study. Front Pharmacol. 2021;12:671859.","journal-title":"Front Pharmacol"},{"key":"1675_CR146","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/s41386-019-0501-x","volume":"44","author":"MV Foga\u00e7a","year":"2019","unstructured":"Foga\u00e7a MV, Fukumoto K, Franklin T, Liu RJ, Duman CH, Vitolo OV, et al. N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology. 2019;44:2230\u20138.","journal-title":"Neuropsychopharmacology."},{"key":"1675_CR147","first-page":"22m03267","volume":"25","author":"C Guidetti","year":"2023","unstructured":"Guidetti C, Serra G, Pani L, Pappagallo M, Maglio G, Martin SD, et al. Subanalysis of subjective cognitive measures from a phase 2, double-blind, randomized trial of REL-1017 in patients with major depressive disorder. Prim Care Companion CNS Disord. 2023;25:22m03267.","journal-title":"Prim Care Companion CNS Disord"},{"key":"1675_CR148","doi-asserted-by":"crossref","first-page":"24m15265","DOI":"10.4088\/JCP.24m15265","volume":"85","author":"M Fava","year":"2024","unstructured":"Fava M, Stahl SM, Pani L, De Martin S, Cutler AJ, Maletic V, et al. Efficacy and safety of Esmethadone (REL-1017) in patients with major depressive disorder and inadequate response to standard antidepressants: a phase 3 randomized controlled trial. J Clin Psychiatry. 2024;85:24m15265.","journal-title":"J Clin Psychiatry"},{"key":"1675_CR149","unstructured":"Relmada Therapeutics, Inc. [Internet]. 2022 [cited 2025 Jun 26]. Relmada therapeutics announces top-line results from phase 3 RELIANCE III Trial for REL-1017 as a monotherapy for the treatment of major depressive disorder. Available from: https:\/\/www.relmada.com\/for-investors\/news\/detail\/269\/relmada-therapeutics-announces-top-line-results-from-phase"},{"key":"1675_CR150","unstructured":"MGGM LLC. A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 as adjunctive treatment for major depressive disorder (MDD) [Internet]. clinicaltrials.gov; 2025 Feb [cited 2025 Jun 26]. Report No.: NCT06735079. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06735079"},{"key":"1675_CR151","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pnpbp.2019.02.001","volume":"92","author":"B Peyrovian","year":"2019","unstructured":"Peyrovian B, Rosenblat JD, Pan Z, Iacobucci M, Brietzke E, McIntyre RS. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2019;92:387\u2013404.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1675_CR152","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1523\/JNEUROSCI.20-11-04037.2000","volume":"20","author":"JNC Kew","year":"2000","unstructured":"Kew JNC, Koester A, Moreau JL, Jenck F, Ouagazzal AM, Mutel V, et al. Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site. J Neurosci. 2000;20:4037\u201349.","journal-title":"J Neurosci"},{"key":"1675_CR153","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1152\/jn.91342.2008","volume":"102","author":"Y Li","year":"2009","unstructured":"Li Y, Krupa B, Kang JS, Bolshakov VY, Liu G. Glycine site of NMDA receptor serves as a spatiotemporal detector of synaptic activity patterns. J Neurophysiol. 2009;102:578\u201389.","journal-title":"J Neurophysiol"},{"key":"1675_CR154","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuropharm.2012.06.051","volume":"64","author":"GL Collingridge","year":"2013","unstructured":"Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M, et al. The NMDA receptor as a target for cognitive enhancement. Neuropharmacology. 2013;64:13\u201326.","journal-title":"Neuropharmacology."},{"key":"1675_CR155","unstructured":"Zhang W, Wang J, Dai J, Zhuo L, Zhao M, Ye H, et al. CA1i pyramidal neurons mediate the role of NMDA receptor subunit GluN3A in depressive behavior and D-serine anti-depression [Internet]. bioRxiv; 2024 [cited 2025 Aug 15]. p. 2024.04.24.590964. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2024.04.24.590964v1"},{"key":"1675_CR156","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1471-4159.1991.tb02131.x","volume":"57","author":"R Haring","year":"1991","unstructured":"Haring R, Stanton PK, Scheideler MA, Moskal JR. Glycine-like modulation of N-methyl-D-aspartate receptors by a monoclonal antibody that enhances long-term potentiation. J Neurochem. 1991;57:323\u201332.","journal-title":"J Neurochem"},{"key":"1675_CR157","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.neuropharm.2005.06.006","volume":"49","author":"JR Moskal","year":"2005","unstructured":"Moskal JR, Kuo AG, Weiss C, Wood PL, O\u2019Connor Hanson A, Kelso S, et al. GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology. 2005;49:1077\u201387.","journal-title":"Neuropharmacology."},{"key":"1675_CR158","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/npp.2012.246","volume":"38","author":"J Burgdorf","year":"2013","unstructured":"Burgdorf J, Zhang X, Nicholson KL, Balster RL, David Leander J, Stanton PK, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2013;38:729\u201342.","journal-title":"Neuropsychopharmacology."},{"key":"1675_CR159","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbr.2015.07.039","volume":"294","author":"J Burgdorf","year":"2015","unstructured":"Burgdorf J, Kroes RA, Zhang X, Gross AL, Schmidt M, Weiss C, et al. Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats. Behav Brain Res. 2015;294:177\u201385.","journal-title":"Behav Brain Res"},{"key":"1675_CR160","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/13543784.2014.852536","volume":"23","author":"JR Moskal","year":"2014","unstructured":"Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs. 2014;23:243\u201354.","journal-title":"Expert Opin Investig Drugs"},{"key":"1675_CR161","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.neuropharm.2008.08.018","volume":"55","author":"X-L Zhang","year":"2008","unstructured":"Zhang X-L, Sullivan JA, Moskal JR, Stanton PK. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology. 2008;55:1238\u201350.","journal-title":"Neuropharmacology."},{"key":"1675_CR162","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.neurobiolaging.2009.04.012","volume":"32","author":"J Burgdorf","year":"2009","unstructured":"Burgdorf J, Zhang X, Weiss C, Matthews E, Disterhoft JF, Stanton PK, et al. The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging. 2009;32:698.","journal-title":"Neurobiol Aging"},{"key":"1675_CR163","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-022-02290-5","volume":"12","author":"M Shen","year":"2022","unstructured":"Shen M, Lv D, Liu X, Wang C. ERK\/mTOR signaling may underlying the antidepressant actions of rapastinel in mice. Transl Psychiatry. 2022;12:522.","journal-title":"Transl Psychiatry"},{"key":"1675_CR164","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2016.09.011","volume":"111","author":"AE Lepack","year":"2016","unstructured":"Lepack AE, Bang E, Lee B, Dwyer JM, Duman RS. Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures. Neuropharmacology. 2016;111:242\u201352.","journal-title":"Neuropharmacology."},{"key":"1675_CR165","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/mp.2017.220","volume":"23","author":"T Kato","year":"2018","unstructured":"Kato T, Foga\u00e7a MV, Deyama S, Li XY, Fukumoto K, Duman RS. BDNF release and signaling are required for the antidepressant actions of GLYX-13. Mol Psychiatry. 2018;23:2007\u201317.","journal-title":"Mol Psychiatry"},{"key":"1675_CR166","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/ph18020157","volume":"18","author":"JE Donello","year":"2025","unstructured":"Donello JE, McIntyre RS, Pickel DB, Stahl SM. Demystifying the antidepressant mechanism of action of stinels, a novel class of neuroplastogens: positive allosteric modulators of the NMDA receptor. Pharmaceuticals (Basel). 2025;18:157.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1675_CR167","doi-asserted-by":"crossref","unstructured":"S P, M M, Do M, G Z, Jr M, Rm B. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21:140\u20139.","DOI":"10.1097\/01.pra.0000462606.17725.93"},{"key":"1675_CR168","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00001756-199612200-00004","volume":"8","author":"M Hokari","year":"1996","unstructured":"Hokari M, Wu HQ, Schwarcz R, Smith QR. Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid. Neuroreport. 1996;8:15\u20138.","journal-title":"Neuroreport."},{"key":"1675_CR169","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1021\/acs.molpharmaceut.0c00727","volume":"18","author":"W Patel","year":"2021","unstructured":"Patel W, Rimmer L, Smith M, Moss L, Smith MA, Snodgrass HR, et al. Probenecid increases the concentration of 7-chlorokynurenic acid derived from the prodrug 4-chlorokynurenine within the prefrontal cortex. Mol Pharmacol. 2021;18:113\u201323.","journal-title":"Mol Pharmacol"},{"key":"1675_CR170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/jpet.115.225664","volume":"355","author":"P Zanos","year":"2015","unstructured":"Zanos P, Piantadosi SC, Wu HQ, Pribut HJ, Dell MJ, Can A, et al. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA\/GlycineB-site inhibition. J Pharmacol Exp Ther. 2015;355:76\u201385.","journal-title":"J Pharmacol Exp Ther"},{"key":"1675_CR171","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ijnp\/pyaa025","volume":"23","author":"LT Park","year":"2020","unstructured":"Park LT, Kadriu B, Gould TD, Zanos P, Greenstein D, Evans JW, et al. A randomized trial of the N-methyl-D-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression. Int J Neuropsychopharmacol. 2020;23:417\u201325.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1675_CR172","unstructured":"VistaGen Therapeutics, Inc. An open-label, drug interaction study to evaluate safety, pharmacokinetic, and pharmacodynamic effect of oral administration of AV-101 alone and in combination with probenecid in healthy subjects [Internet]. clinicaltrials.gov; 2022 Mar [cited 2025 Jun 26]. Report No.: NCT05280054. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05280054"},{"key":"1675_CR173","unstructured":"VistaGen Therapeutics, Inc. Double-blind, placebo-controlled, phase 2 trial to test efficacy and safety of AV-101 (L-4-chlorokynurenine) as adjunct to current antidepressant therapy in patients with major depressive disorder (the ELEVATE Study) [Internet]. clinicaltrials.gov; 2019 Oct [cited 2025 Jun 26]. Report No.: NCT03078322. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03078322"},{"key":"1675_CR174","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1176\/ajp.115.11.1025","volume":"115","author":"GE Crane","year":"1959","unstructured":"Crane GE. Cyloserine as an antidepressant agent. Am J Psychiatry. 1959;115:1025\u20136.","journal-title":"Am J Psychiatry"},{"key":"1675_CR175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0304-3940(89)90379-0","volume":"98","author":"WF Hood","year":"1989","unstructured":"Hood WF, Compton RP, Monahan JB. D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett. 1989;98:91\u20135.","journal-title":"Neurosci Lett"},{"key":"1675_CR176","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0006-8993(90)90745-W","volume":"510","author":"GB Watson","year":"1990","unstructured":"Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 1990;510:158\u201360.","journal-title":"Brain Res"},{"key":"1675_CR177","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-2999(96)00675-9","volume":"316","author":"M Papp","year":"1996","unstructured":"Papp M, Moryl E. Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol. 1996;316:145\u201351.","journal-title":"Eur J Pharmacol"},{"key":"1675_CR178","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0014-2999(92)94837-L","volume":"223","author":"Y Watanabe","year":"1992","unstructured":"Watanabe Y, Saito H, Abe K. Effects of glycine and structurally related amino acids on generation of long-term potentiation in rat hippocampal slices. Eur J Pharmacol. 1992;223:179\u201384.","journal-title":"Eur J Pharmacol"},{"key":"1675_CR179","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/sj.bjp.0705541","volume":"140","author":"E Rouaud","year":"2003","unstructured":"Rouaud E, Billard JM. D-Cycloserine facilitates synaptic plasticity but impairs glutamatergic neurotransmission in rat hippocampal slices. Br J Pharmacol. 2003;140:1051\u20136.","journal-title":"Br J Pharmacol"},{"key":"1675_CR180","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.npp.1300517","volume":"29","author":"MA Nitsche","year":"2004","unstructured":"Nitsche MA, Jaussi W, Liebetanz D, Lang N, Tergau F, Paulus W. Consolidation of human motor cortical neuroplasticity by D-cycloserine. Neuropsychopharmacology. 2004;29:1573\u20138.","journal-title":"Neuropsychopharmacology."},{"key":"1675_CR181","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.schres.2014.01.016","volume":"153","author":"CK Cain","year":"2014","unstructured":"Cain CK, McCue M, Bello I, Creedon T, Tang DI, Laska E, et al. D-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophr Res. 2014;153:177\u201383.","journal-title":"Schizophr Res"},{"key":"1675_CR182","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/appi.ajp.2013.12070974","volume":"170","author":"SG Hofmann","year":"2013","unstructured":"Hofmann SG, Smits JAJ, Rosenfield D, Simon N, Otto MW, Meuret AE, et al. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013;170:751\u20138.","journal-title":"Am J Psychiatry"},{"key":"1675_CR183","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.biopsych.2009.07.036","volume":"67","author":"MW Otto","year":"2010","unstructured":"Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010;67:365\u201370.","journal-title":"Biol Psychiatry"},{"key":"1675_CR184","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0091-3057(89)90571-6","volume":"34","author":"JB Monahan","year":"1989","unstructured":"Monahan JB, Handelmann GE, Hood WF, Cordi AA. D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav. 1989;34:649\u201353.","journal-title":"Pharmacol Biochem Behav"},{"key":"1675_CR185","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00213-011-2330-4","volume":"218","author":"P Bado","year":"2011","unstructured":"Bado P, Madeira C, Vargas-Lopes C, Moulin TC, Wasilewska-Sampaio AP, Maretti L, et al. Effects of low-dose D-serine on recognition and working memory in mice. Psychopharmacology (Berl). 2011;218:461\u201370.","journal-title":"Psychopharmacology (Berl)"},{"key":"1675_CR186","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jad.2006.03.004","volume":"93","author":"U Heresco-Levy","year":"2006","unstructured":"Heresco-Levy U, Javitt DC, Gelfin Y, Gorelik E, Bar M, Blanaru M, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord. 2006;93:239\u201343.","journal-title":"J Affect Disord"},{"key":"1675_CR187","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145712000910","volume":"16","author":"U Heresco-Levy","year":"2013","unstructured":"Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, et al. A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol. 2013;16:501\u20136.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1675_CR188","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jamapsychiatry.2022.3255","volume":"79","author":"J Cole","year":"2022","unstructured":"Cole J, Sohn MN, Harris AD, Bray SL, Patten SB, McGirr A. Efficacy of adjunctive D-cycloserine to intermittent theta-burst stimulation for major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79:1153\u201361.","journal-title":"JAMA Psychiatry"},{"key":"1675_CR189","doi-asserted-by":"crossref","DOI":"10.1186\/s40345-023-00308-5","volume":"11","author":"A Nierenberg","year":"2023","unstructured":"Nierenberg A, Lavin P, Javitt DC, Shelton R, Sapko MT, Mathew S, et al. NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial. Int J Bipolar Disord. 2023;11:28.","journal-title":"Int J Bipolar Disord"},{"key":"1675_CR190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coph.2014.10.009","volume":"20","author":"S Zhu","year":"2015","unstructured":"Zhu S, Paoletti P. Allosteric modulators of NMDA receptors: multiple sites and mechanisms. Curr Opin Pharmacol. 2015;20:14\u201323.","journal-title":"Curr Opin Pharmacol"},{"key":"1675_CR191","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0026-895X(25)13275-6","volume":"44","author":"K Williams","year":"1993","unstructured":"Williams K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol. 1993;44:851\u20139.","journal-title":"Mol Pharmacol"},{"key":"1675_CR192","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.neuron.2016.08.014","volume":"91","author":"F Yi","year":"2016","unstructured":"Yi F, Mou TC, Dorsett KN, Volkmann RA, Menniti FS, Sprang SR, et al. Structural basis for negative allosteric modulation of GluN2A-containing NMDA receptors. Neuron. 2016;91:1316\u201329.","journal-title":"Neuron."},{"key":"1675_CR193","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1124\/jpet.110.174144","volume":"335","author":"BM Costa","year":"2010","unstructured":"Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, et al. A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther. 2010;335:614\u201321.","journal-title":"J Pharmacol Exp Ther"},{"key":"1675_CR194","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1038\/emboj.2011.203","volume":"30","author":"L Mony","year":"2011","unstructured":"Mony L, Zhu S, Carvalho S, Paoletti P. Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines. EMBO J. 2011;30:3134\u201346.","journal-title":"EMBO J"},{"key":"1675_CR195","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1124\/mol.113.085209","volume":"83","author":"KK Ogden","year":"2013","unstructured":"Ogden KK, Traynelis SF. Contribution of the M1 transmembrane helix and pre-M1 region to positive allosteric modulation and gating of N-methyl-D-aspartate receptors. Mol Pharmacol. 2013;83:1045\u201356.","journal-title":"Mol Pharmacol"},{"key":"1675_CR196","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","volume":"28","author":"SH Preskorn","year":"2008","unstructured":"Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28:631\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"1675_CR197","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/0269881117746901","volume":"32","author":"H Tang","year":"2018","unstructured":"Tang H, Kukral D, Li YW, Fronheiser M, Malone H, Pena A, et al. Mapping the central effects of (\u00b1)-ketamine and traxoprodil using pharmacological magnetic resonance imaging in awake rats. J Psychopharmacol. 2018;32:146\u201355.","journal-title":"J Psychopharmacol"},{"key":"1675_CR198","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HRP.0000000000000183","volume":"26","author":"ID Henter","year":"2018","unstructured":"Henter ID, de Sousa RT, Zarate CA. Glutamatergic modulators in depression. Harv Rev Psychiatry. 2018;26:307\u201319.","journal-title":"Harv Rev Psychiatry"},{"key":"1675_CR199","unstructured":"Naurex, Inc, an affiliate of Allergan plc. A randomized, double-blind, placebo-controlled multiple oral ascending dose study of the safety, tolerability and pharmacokinetics of NRX-1074 in normal healthy volunteers [Internet]. clinicaltrials.gov; 2016 Feb [cited 2025 Jun 25]. Report No.: NCT02366364. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02366364"},{"key":"1675_CR200","unstructured":"Naurex, Inc, an affiliate of Allergan plc. A randomized, double-blind, placebo-controlled single intravenous and oral ascending dose study of the safety, tolerability and pharmacokinetics of NRX-1074 in normal healthy volunteers [Internet]. clinicaltrials.gov; 2016 Jan [cited 2025 Jun 25]. Report No.: NCT01856556. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01856556"},{"key":"1675_CR201","unstructured":"Gate Neurosciences, Inc. A randomized, double-blind, placebo-controlled, single dose and multiple ascending dose, single center phase1 study of safety, tolerability, pharmacokinetics, and electroencephalography of Intravenous GATE-202 in healthy volunteers [Internet]. clinicaltrials.gov; 2023 Apr [cited 2025 Jun 25]. Report No.: NCT05597241. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05597241"},{"key":"1675_CR202","unstructured":"Naurex, Inc, an affiliate of Allergan plc. Phase 2, randomized, double-blind, multiple-dose level, placebo controlled, single intravenous dose, parallel efficacy and safety study of NRX-1074 in subjects with major depressive disorder [Internet]. clinicaltrials.gov; 2016 Feb [cited 2025 Jun 25]. Report No.: NCT02067793. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02067793"},{"key":"1675_CR203","unstructured":"Syndeio Biosciences [Internet]. [cited 2025 Jun 25]. Gate neurosciences and University of Pittsburgh collaborate to initiate phase 2 trial combining apimostinel with digital therapeutic for depression. Available from: https:\/\/www.syndeio.bio\/news\/gate-neurosciences-and-university-of-pittsburgh-collaborate-to-initiate-phase-2-trial-combining-apimostinel-with-digital-therapeutic-for-depression"},{"key":"1675_CR204","unstructured":"NYU Langone Health. A placebo-controlled two-dose trial of NRX-1074 early in the course of schizophrenia [Internet]. clinicaltrials.gov; 2016 Feb [cited 2025 Jun 25]. Report No.: NCT02603458. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02603458"},{"key":"1675_CR205","doi-asserted-by":"crossref","first-page":"110100","DOI":"10.1016\/j.neuropharm.2024.110100","volume":"259","author":"LiYX Zhang Xlei","year":"2024","unstructured":"Zhang Xlei LiYX, Berglund N, Burgdorf JS, Donello JE, Moskal JR, et al. Zelquistinel acts at an extracellular binding domain to modulate intracellular calcium inactivation of N-methyl-D-aspartate receptors. Neuropharmacology. 2024;259:110100.","journal-title":"Neuropharmacology."},{"key":"1675_CR206","first-page":"799","volume":"46","author":"S Pothula","year":"2021","unstructured":"Pothula S, Liu RJ, Wu M, Sliby AN, Picciotto MR, Banerjee P, et al. Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons. Neuropharmacology. 2021;46:799\u2013808.","journal-title":"Neuropharmacology"},{"key":"1675_CR207","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/ijnp\/pyac043","volume":"25","author":"JS Burgdorf","year":"2022","unstructured":"Burgdorf JS, Zhang XL, Stanton PK, Moskal JR, Donello JE. Zelquistinel is an orally bioavailable novel NMDA receptor allosteric modulator that exhibits rapid and sustained antidepressant-like effects. Int J Neuropsychopharmacol. 2022;25:979\u201391.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1675_CR208","unstructured":"Gate Neurosciences, Inc. A double-blind, placebo-controlled, fixed-dose study of AGN-241751 in adult participants with major depressive disorder [Internet]. clinicaltrials.gov; 2022 Aug [cited 2025 Jun 25]. Report No.: NCT03586427. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03586427"},{"key":"1675_CR209","unstructured":"Gate Neurosciences, Inc. A two-part, double-blind, placebo-controlled, single- and multiple-dose (Part A) or twice daily dose (Part B) study of AGN-241751 in adult participants with major depressive disorder [Internet]. clinicaltrials.gov; 2023 Jul [cited 2025 Jun 25]. Report No.: NCT03726658. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03726658"},{"key":"1675_CR210","unstructured":"Gate Neurosciences, Inc. A phase 2, multicenter, randomized, double-blind evaluation of the efficacy and safety of oral GATE-251 or placebo for the reduction of symptoms of major depressive disorder in adults [Internet]. clinicaltrials.gov; 2025 Jun [cited 2025 Jun 25]. Report No.: NCT06547489. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06547489"},{"key":"1675_CR211","unstructured":"Syndeio Biosciences [Internet]. 2025 [cited 2025 Jun 25]. Syndeio Biosciences. Available from: https:\/\/www.syndeio.bio"},{"key":"1675_CR212","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186:693\u2013714.","journal-title":"Cell."},{"key":"1675_CR213","doi-asserted-by":"crossref","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","volume":"10","author":"MG Erkkinen","year":"2018","unstructured":"Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018;10:a033118.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1675_CR214","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet."},{"key":"1675_CR215","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. Lancet. 2021;397:2284\u2013303.","journal-title":"Lancet."},{"key":"1675_CR216","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijms22168363","volume":"22","author":"A Kim","year":"2021","unstructured":"Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo PS, Rosenstock TR, et al. New avenues for the treatment of Huntington\u2019s disease. Int J Mol Sci. 2021;22:8363.","journal-title":"Int J Mol Sci"},{"key":"1675_CR217","doi-asserted-by":"crossref","first-page":"e075037","DOI":"10.1136\/bmj-2023-075037","volume":"383","author":"H Ilieva","year":"2023","unstructured":"Ilieva H, Vullaganti M, Kwan J. Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis. BMJ. 2023;383:e075037.","journal-title":"BMJ."},{"key":"1675_CR218","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-023-00823-1","volume":"23","author":"B Dejanovic","year":"2024","unstructured":"Dejanovic B, Sheng M, Hanson JE. Targeting synapse function and loss for treatment of neurodegenerative diseases. Nat Rev Drug Discov. 2024;23:23\u201342.","journal-title":"Nat Rev Drug Discov"},{"key":"1675_CR219","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0163-7258(98)00042-4","volume":"81","author":"A Doble","year":"1999","unstructured":"Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther. 1999;81:163\u2013221.","journal-title":"Pharmacol Ther"},{"key":"1675_CR220","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nm.2056","volume":"15","author":"O Sichi","year":"2009","unstructured":"Sichi O, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 2009;15:1407\u201313.","journal-title":"Nat Med"},{"key":"1675_CR221","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","volume":"11","author":"GE Hardingham","year":"2010","unstructured":"Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682\u201396.","journal-title":"Nat Rev Neurosci"},{"key":"1675_CR222","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1073\/pnas.0511065103","volume":"103","author":"G Amadoro","year":"2006","unstructured":"Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK\/MAPK activation. Proc Natl Acad Sci USA. 2006;103:2892\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1675_CR223","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1523\/JNEUROSCI.5326-05.2006","volume":"26","author":"F Gardoni","year":"2006","unstructured":"Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G, et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci. 2006;26:2914\u201322.","journal-title":"J Neurosci"},{"key":"1675_CR224","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-7258(02)00302-9","volume":"97","author":"JM Loftis","year":"2003","unstructured":"Loftis JM, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther. 2003;97:55\u201385.","journal-title":"Pharmacol Ther"},{"key":"1675_CR225","doi-asserted-by":"crossref","first-page":"8231","DOI":"10.1002\/alz.14125","volume":"20","author":"S Escamilla","year":"2024","unstructured":"Escamilla S, Badillos R, Comella JX, Sol\u00e9 M, P\u00e9rez-Ota\u00f1o I, Mut JVS, et al. Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer\u2019s disease patients. Alzheimers Dement. 2024;20:8231\u201345.","journal-title":"Alzheimers Dement"},{"key":"1675_CR226","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jnc.15007","volume":"154","author":"S Li","year":"2020","unstructured":"Li S, Selkoe DJ. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A\u03b2 oligomers from Alzheimer\u2019s brain. J Neurochem. 2020;154:583\u201397.","journal-title":"J Neurochem"},{"key":"1675_CR227","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.129","volume":"4","author":"C Tackenberg","year":"2013","unstructured":"Tackenberg C, Grinschgl S, Trutzel A, Santuccione AC, Frey MC, Konietzko U, et al. NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis. 2013;4:e608.","journal-title":"Cell Death Dis"},{"key":"1675_CR228","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nbd.2012.05.013","volume":"48","author":"AJ Milnerwood","year":"2012","unstructured":"Milnerwood AJ, Kaufman AM, Sepers MD, Gladding CM, Zhang L, Wang L, et al. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington\u2019s disease mice. Neurobiol Dis. 2012;48:40\u201351.","journal-title":"Neurobiol Dis"},{"key":"1675_CR229","doi-asserted-by":"crossref","first-page":"590569","DOI":"10.3389\/fncel.2020.590569","volume":"14","author":"ME Schmidt","year":"2020","unstructured":"Schmidt ME, Caron NS, Aly AE, Lemari\u00e9 FL, Dal Cengio L, Ko Y, et al. DAPK1 promotes extrasynaptic GluN2B phosphorylation and striatal spine instability in the YAC128 mouse model of Huntington disease. Front Cell Neurosci. 2020;14:590569.","journal-title":"Front Cell Neurosci"},{"key":"1675_CR230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fnsyn.2019.00003","volume":"11","author":"R Kang","year":"2019","unstructured":"Kang R, Wang L, Sanders SS, Zuo K, Hayden MR, Raymond LA. Altered regulation of striatal neuronal N-methyl-D-aspartate receptor trafficking by palmitoylation in Huntington disease mouse model. Front Synaptic Neurosci. 2019;11:3.","journal-title":"Front Synaptic Neurosci"},{"key":"1675_CR231","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.neurobiolaging.2003.04.003","volume":"24","author":"L Li","year":"2003","unstructured":"Li L, Fan M, Icton CD, Chen N, Leavitt BR, Hayden MR, et al. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging. 2003;24:1113\u201321.","journal-title":"Neurobiol Aging"},{"key":"1675_CR232","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","volume":"38","author":"CG Parsons","year":"1999","unstructured":"Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology. 1999;38:735\u201367.","journal-title":"Neuropharmacology."},{"key":"1675_CR233","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/nm.3246","volume":"19","author":"S Marco","year":"2013","unstructured":"Marco S, Giralt A, Petrovic MM, Pouladi MA, Mart\u00ednez-Turrillas R, Mart\u00ednez-Hern\u00e1ndez J, et al. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington\u2019s disease models. Nat Med. 2013;19:1030\u20138.","journal-title":"Nat Med"},{"key":"1675_CR234","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ymthe.2018.05.013","volume":"26","author":"S Marco","year":"2018","unstructured":"Marco S, Murillo A, P\u00e9rez-Ota\u00f1o I. RNAi-based GluN3A silencing prevents and reverses disease phenotypes induced by mutant huntingtin. Mol Ther. 2018;26:1965\u201372.","journal-title":"Mol Ther"},{"key":"1675_CR235","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jamaneurol.2014.3953","volume":"72","author":"JF Wesseling","year":"2015","unstructured":"Wesseling JF, P\u00e9rez-Ota\u00f1o I. Modulation of GluN3A expression in Huntington disease: a new N-methyl-D-aspartate receptor-based therapeutic approach? JAMA Neurol. 2015;72:468\u201373.","journal-title":"JAMA Neurol"},{"key":"1675_CR236","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1021\/acs.jmedchem.2c00313","volume":"65","author":"MD Hill","year":"2022","unstructured":"Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. SAGE-718: a first-in-class N-methyl-D-aspartate receptor positive allosteric modulator for the potential treatment of cognitive impairment. J Med Chem. 2022;65:9063\u201375.","journal-title":"J Med Chem"},{"key":"1675_CR237","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/bph.16235","volume":"181","author":"JT Beckley","year":"2024","unstructured":"Beckley JT, Aman TK, Ackley MA, Kazdoba TM, Lewis MC, Smith AC, et al. Pharmacological characterization of SAGE-718, a novel positive allosteric modulator of N-methyl-D-aspartate receptors. Br J Pharmacol. 2024;181:1028\u201350.","journal-title":"Br J Pharmacol"},{"key":"1675_CR238","doi-asserted-by":"crossref","first-page":"e13852","DOI":"10.1111\/cts.13852","volume":"17","author":"A Koenig","year":"2024","unstructured":"Koenig A, Lewis M, Wald J, Li S, Varoglu M, Dai J, et al. Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington\u2019s disease. Clin Transl Sci. 2024;17:e13852.","journal-title":"Clin Transl Sci"},{"key":"1675_CR239","unstructured":"Sage Therapeutics. A randomized, placebo-controlled, double-blind study to evaluate the effect of SAGE-718 on cognitive function in participants with Huntington's disease [Internet]. clinicaltrials.gov; 2025 Mar [cited 2025 Jun 25]. Report No.: NCT05107128. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05107128"},{"key":"1675_CR240","unstructured":"Sage Therapeutics. A phase 3, multicenter, open-label safety study to evaluate the long-term safety and tolerability of SAGE-718 in participants with Huntington's disease [Internet]. clinicaltrials.gov; 2025 Jan [cited 2025 Jun 25]. Report No.: NCT05655520. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05655520"},{"key":"1675_CR241","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/mds.27962","volume":"35","author":"AL Barth","year":"2020","unstructured":"Barth AL, Schneider JS, Johnston TH, Hill MP, Brotchie JM, Moskal JR, et al. NYX-458 improves cognitive performance in a primate Parkinson\u2019s disease model. Mov Disord. 2020;35:640\u20139.","journal-title":"Mov Disord"},{"key":"1675_CR242","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ijnp\/pyx096","volume":"21","author":"MA Khan","year":"2018","unstructured":"Khan MA, Houck DR, Gross AL, Zhang XL, Cearley C, Madsen TM, et al. NYX-2925 is a novel NMDA receptor-specific spirocyclic-\u03b2-lactam that modulates synaptic plasticity processes associated with learning and memory. Int J Neuropsychopharmacol. 2018;21:242\u201354.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1675_CR243","unstructured":"Publications [Internet]. Aptinyx. [cited 2025 Jun 25]. Available from: https:\/\/www.aptinyx.com\/pipeline\/publications\/"},{"key":"1675_CR244","unstructured":"Aptinyx reports results from phase 2 study of NYX-458 in cognitive impairment associated with Parkinson\u2019s disease and dementia with Lewy bodies and provides pipeline and corporate update [Internet]. [cited 2025 Jun 25]. Available from: https:\/\/ir.aptinyx.com\/press-releases\/news-details\/2023\/Aptinyx-Reports-Results-from-Phase-2-Study-of-NYX-458-in-Cognitive-Impairment-Associated-with-Parkinsons-Disease-and-Dementia-with-Lewy-Bodies-and-Provides-Pipeline-and-Corporate-Update\/default.aspxs"},{"key":"1675_CR245","unstructured":"Aptinyx. A study to evaluate NYX-458 in subjects with mild cognitive impairment or mild dementia associated with Parkinson's disease or prodromal or manifest Lewy body dementia [Internet]. clinicaltrials.gov; 2022 Oct [cited 2025 Jun 25]. Report No.: NCT04148391. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04148391"},{"key":"1675_CR246","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1586\/ecp.11.17","volume":"4","author":"HY Zhou","year":"2011","unstructured":"Zhou HY, Chen SR, Pan HL, Targeting. N-methyl-D-aspartate receptors for treatment of neuropathic pain. Expert Rev Clin Pharmacol. 2011;4:379\u201388.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1675_CR247","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/biomedicines5020015","volume":"5","author":"G Littlejohn","year":"2017","unstructured":"Littlejohn G, Guymer E. Modulation of NMDA receptor activity in fibromyalgia. Biomedicines. 2017;5:15.","journal-title":"Biomedicines."},{"key":"1675_CR248","doi-asserted-by":"crossref","first-page":"7723","DOI":"10.1073\/pnas.96.14.7723","volume":"96","author":"CJ Woolf","year":"1999","unstructured":"Woolf CJ, Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci USA. 1999;96:7723\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1675_CR249","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0165-0173(02)00202-3","volume":"40","author":"WD Willis","year":"2002","unstructured":"Willis WD. Long-term potentiation in spinothalamic neurons. Brain Res Brain Res Rev. 2002;40:202\u201314.","journal-title":"Brain Res Brain Res Rev"},{"key":"1675_CR250","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0304-3959(91)90100-C","volume":"44","author":"CJ Woolf","year":"1991","unstructured":"Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain. 1991;44:293.","journal-title":"Pain."},{"key":"1675_CR251","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1126\/science.288.5472.1765","volume":"288","author":"CJ Woolf","year":"2000","unstructured":"Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765\u20139.","journal-title":"Science."},{"key":"1675_CR252","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpain.2009.06.012","volume":"10","author":"A Latremoliere","year":"2009","unstructured":"Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895\u2013926.","journal-title":"J Pain"},{"key":"1675_CR253","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/306686a0","volume":"306","author":"CJ Woolf","year":"1983","unstructured":"Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature. 1983;306:686\u20138.","journal-title":"Nature."},{"key":"1675_CR254","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0006-8993(87)91487-9","volume":"424","author":"SN Davies","year":"1987","unstructured":"Davies SN, Lodge D. Evidence for involvement of N-methylaspartate receptors in \u2018wind-up\u2019 of class 2 neurones in the dorsal horn of the rat. Brain Res. 1987;424:402\u20136.","journal-title":"Brain Res"},{"key":"1675_CR255","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/0028-3908(87)90275-9","volume":"26","author":"AH Dickenson","year":"1987","unstructured":"Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology. 1987;26:1235\u20138.","journal-title":"Neuropharmacology."},{"key":"1675_CR256","doi-asserted-by":"crossref","first-page":"11107","DOI":"10.1523\/JNEUROSCI.1678-05.2005","volume":"25","author":"LJ Wu","year":"2005","unstructured":"Wu LJ, Toyoda H, Zhao MG, Lee YS, Tang J, Ko SW, et al. Upregulation of forebrain NMDA NR2B receptors contributes to behavioral sensitization after inflammation. J Neurosci. 2005;25:11107\u201316.","journal-title":"J Neurosci"},{"key":"1675_CR257","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1213\/00000539-199377020-00026","volume":"77","author":"CJ Woolf","year":"1993","unstructured":"Woolf CJ, Chong MS. Preemptive analgesia-treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg. 1993;77:362\u201379.","journal-title":"Anesth Analg"},{"key":"1675_CR258","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0885-3924(00)00213-X","volume":"20","author":"K Fisher","year":"2000","unstructured":"Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage. 2000;20:358\u201373.","journal-title":"J Pain Symptom Manage"},{"key":"1675_CR259","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1097\/00002508-200006001-00013","volume":"16","author":"DJ Hewitt","year":"2000","unstructured":"Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain. 2000;16:S73\u201379.","journal-title":"Clin J Pain"},{"key":"1675_CR260","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.3390\/nu12082184","volume":"12","author":"HJ Shin","year":"2020","unstructured":"Shin HJ, Na HS, Do SH. Magnesium and pain. Nutrients. 2020;12:2184.","journal-title":"Nutrients."},{"key":"1675_CR261","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/0259-1162.143110","volume":"8","author":"MS Kurdi","year":"2014","unstructured":"Kurdi MS, Theerth KA, Deva RS. Ketamine: Current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8:283\u201390.","journal-title":"Anesth Essays Res"},{"key":"1675_CR262","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/acem.14159","volume":"28","author":"N Balzer","year":"2021","unstructured":"Balzer N, McLeod SL, Walsh C, Grewal K. Low-dose ketamine for acute pain control in the emergency department: a systematic review and Meta-analysis. Acad Emerg Med. 2021;28:444\u201354.","journal-title":"Acad Emerg Med"},{"key":"1675_CR263","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/cts.12584","volume":"12","author":"DR Houck","year":"2019","unstructured":"Houck DR, Sindelar L, Sanabria CR, Stanworth SH, Krueger M, Suh M, et al. NYX-2925, a novel N-methyl-D-aspartate receptor modulator: a first-in-human, randomized, double-blind study of safety and pharmacokinetics in adults. Clin Transl Sci. 2019;12:164\u201371.","journal-title":"Clin Transl Sci"},{"key":"1675_CR264","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/jpet.118.249409","volume":"366","author":"N Ghoreishi-Haack","year":"2018","unstructured":"Ghoreishi-Haack N, Priebe JM, Aguado JD, Colechio EM, Burgdorf JS, Bowers MS, et al. NYX-2925 is a novel N-methyl-D-aspartate receptor modulator that induces rapid and long-lasting analgesia in rat models of neuropathic pain. J Pharmacol Exp Ther. 2018;366:485\u201397.","journal-title":"J Pharmacol Exp Ther"},{"key":"1675_CR265","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/jnc.14845","volume":"152","author":"MS Bowers","year":"2020","unstructured":"Bowers MS, Cacheaux LP, Sahu SU, Schmidt ME, Sennello JA, Leaderbrand K, et al. NYX-2925 induces metabotropic N-methyl-D-aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor. J Neurochem. 2020;152:523\u201341.","journal-title":"J Neurochem"},{"key":"1675_CR266","doi-asserted-by":"crossref","first-page":"100039","DOI":"10.1016\/j.ynpai.2019.100039","volume":"7","author":"G Morrison","year":"2020","unstructured":"Morrison G, Asiedu MN, Priebe JM, Dunning J, Ghoreishi-Haack N, Kroes RA, et al. The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC. Neurobiol Pain. 2020;7:100039.","journal-title":"Neurobiol Pain."},{"key":"1675_CR267","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1007\/s00213-019-05341-w","volume":"236","author":"JS Burgdorf","year":"2019","unstructured":"Burgdorf JS, Christian EP, S\u00f8rensen L, Stanton PK, Leaderbrand K, Madsen TM, et al. A translational EEG-based approach to assess modulation of long-lasting NMDAR-dependent synaptic plasticity. Psychopharmacology (Berl). 2019;236:3687\u201393.","journal-title":"Psychopharmacology (Berl)"},{"key":"1675_CR268","unstructured":"Aptinyx. A randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to assess the efficacy and safety of NYX-2925 in subjects with neuropathic pain associated with diabetic peripheral neuropathy [Internet]. clinicaltrials.gov; 2020 Jun [cited 2025 Jun 24]. Report No.: NCT03219320. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03219320"},{"key":"1675_CR269","unstructured":"Robust analgesic activity of Aptinyx\u2019s NYX-2925 in advanced DPN patients revealed through further analysis of data from phase 2 study - aptinyx [Internet]. [cited 2025 Jun 24]. Available from https:\/\/www.aptinyx.com\/ir-sub\/news-releases\/news-release-details\/robust-analgesic-activity-aptinyxs-nyx-2925-advanced-dpn\/"},{"key":"1675_CR270","unstructured":"Aptinyx reports results from phase 2b study of NYX-2925 in painful diabetic peripheral neuropathy [Internet]. [cited 2025 Jun 24]. Available from: https:\/\/www.businesswire.com\/news\/home\/20220407005385\/en\/Aptinyx-Reports-Results-from-Phase-2b-Study-of-NYX-2925-in-Painful-Diabetic-Peripheral-Neuropathy"},{"key":"1675_CR271","unstructured":"Aptinyx. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NYX-2925 in subjects with neuropathic pain associated with diabetic peripheral neuropathy [Internet]. clinicaltrials.gov; 2023 Apr [cited 2025 Jun 24]. Report No.: NCT04146896. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04146896"},{"key":"1675_CR272","unstructured":"Aptinyx. A phase 2, single-blind, exploratory, placebo-controlled, pilot study to assess the efficacy and safety of daily oral NYX-2925 in subjects with fibromyalgia [Internet]. clinicaltrials.gov; 2022 Aug [cited 2025 Jun 24]. Report No.: NCT03249103. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03249103"},{"key":"1675_CR273","unstructured":"Aptinyx. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NYX-2925 in subjects with fibromyalgia [Internet]. clinicaltrials.gov; 2023 Apr [cited 2025 Jun 24]. Report No.: NCT04147858. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04147858"},{"key":"1675_CR274","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41573-024-00981-w","volume":"23","author":"P Klein","year":"2024","unstructured":"Klein P, Kaminski RM, Koepp M, L\u00f6scher W. New epilepsy therapies in development. Nat Rev Drug Discov. 2024;23:682\u2013708.","journal-title":"Nat Rev Drug Discov"},{"key":"1675_CR275","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","volume":"51","author":"AK Ngugi","year":"2010","unstructured":"Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51:883\u201390.","journal-title":"Epilepsia."},{"key":"1675_CR276","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279\u201386.","journal-title":"JAMA Neurol"},{"key":"1675_CR277","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/biom10030464","volume":"10","author":"T Hanada","year":"2020","unstructured":"Hanada T. Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors. Biomolecules. 2020;10:464.","journal-title":"Biomolecules."},{"key":"1675_CR278","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0301-0082(95)00030-5","volume":"47","author":"HF Bradford","year":"1995","unstructured":"Bradford HF. Glutamate, GABA and epilepsy. Prog Neurobiol. 1995;47:477\u2013511.","journal-title":"Prog Neurobiol"},{"key":"1675_CR279","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/326701a0","volume":"326","author":"I Mody","year":"1987","unstructured":"Mody I, Heinemann U. NMDA receptors of dentate gyrus granule cells participate in synaptic transmission following kindling. Nature. 1987;326:701\u20134.","journal-title":"Nature."},{"key":"1675_CR280","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ajhg.2016.07.013","volume":"99","author":"D Li","year":"2016","unstructured":"Li D, Yuan H, Ortiz-Gonzalez XR, Marsh ED, Tian L, McCormick EM, et al. GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet. 2016;99:802\u201316.","journal-title":"Am J Hum Genet"},{"key":"1675_CR281","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1093\/brain\/awz232","volume":"142","author":"W XiangWei","year":"2019","unstructured":"XiangWei W, Kannan V, Xu Y, Kosobucki GJ, Schulien AJ, Kusumoto H, et al. Heterogeneous clinical and functional features of GRIN2D-related developmental and epileptic encephalopathy. Brain. 2019;142:3009\u201327.","journal-title":"Brain."},{"key":"1675_CR282","doi-asserted-by":"crossref","first-page":"e1006536","DOI":"10.1371\/journal.pgen.1006536","volume":"13","author":"KK Ogden","year":"2017","unstructured":"Ogden KK, Chen W, Swanger SA, McDaniel MJ, Fan LZ, Hu C, et al. Molecular mechanism of disease-associated mutations in the Pre-M1 helix of NMDA receptors and potential rescue pharmacology. PLoS Genet. 2017;13:e1006536.","journal-title":"PLoS Genet"},{"key":"1675_CR283","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/epi.12987","volume":"56","author":"C Ohba","year":"2015","unstructured":"Ohba C, Shiina M, Tohyama J, Haginoya K, Lerman-Sagie T, Okamoto N, et al. GRIN1 mutations cause encephalopathy with infantile-onset epilepsy, and hyperkinetic and stereotyped movement disorders. Epilepsia. 2015;56:841\u20138.","journal-title":"Epilepsia."},{"key":"1675_CR284","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s12264-017-0191-5","volume":"34","author":"XX Xu","year":"2018","unstructured":"Xu XX, Luo JH. Mutations of N-methyl-D-aspartate receptor subunits in epilepsy. Neurosci Bull. 2018;34:549\u201365.","journal-title":"Neurosci Bull"},{"key":"1675_CR285","volume":"11","author":"U Pfisterer","year":"2020","unstructured":"Pfisterer U, Petukhov V, Demharter S, Meichsner J, Thompson JJ, Batiuk MY, et al. Identification of epilepsy-associated neuronal subtypes and gene expression underlying epileptogenesis. Nat Commun. 2020;11:5038.","journal-title":"Nat Commun"},{"key":"1675_CR286","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1113\/jphysiol.1994.sp020259","volume":"478","author":"RD Traub","year":"1994","unstructured":"Traub RD, Jefferys JG, Whittington MA. Enhanced NMDA conductance can account for epileptiform activity induced by low Mg2+ in the rat hippocampal slice. J Physiol. 1994;478:379\u201393.","journal-title":"J Physiol"},{"key":"1675_CR287","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1152\/jn.1998.79.1.418","volume":"79","author":"PR Patrylo","year":"1998","unstructured":"Patrylo PR, Dudek FE. Physiological unmasking of new glutamatergic pathways in the dentate gyrus of hippocampal slices from kainate-induced epileptic rats. J Neurophysiol. 1998;79:418\u201329.","journal-title":"J Neurophysiol"},{"key":"1675_CR288","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1113\/jphysiol.1993.sp019527","volume":"461","author":"RD Traub","year":"1993","unstructured":"Traub RD, Miles R, Jefferys JG. Synaptic and intrinsic conductances shape picrotoxin-induced synchronized after-discharges in the guinea-pig hippocampal slice. J Physiol. 1993;461:525\u201347.","journal-title":"J Physiol"},{"key":"1675_CR289","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1523\/JNEUROSCI.3607-06.2007","volume":"27","author":"Q Chen","year":"2007","unstructured":"Chen Q, He S, Hu XL, Yu J, Zhou Y, Zheng J, et al. Differential roles of NR2A- and NR2B-containing NMDA receptors in activity-dependent brain-derived neurotrophic factor gene regulation and limbic epileptogenesis. J Neurosci. 2007;27:542\u201352.","journal-title":"J Neurosci"},{"key":"1675_CR290","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eplepsyres.2013.01.007","volume":"105","author":"AS Synowiec","year":"2013","unstructured":"Synowiec AS, Singh DS, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res. 2013;105:183\u20138.","journal-title":"Epilepsy Res"},{"key":"1675_CR291","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/epi.12247","volume":"54","author":"N Gaspard","year":"2013","unstructured":"Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54:1498\u2013503.","journal-title":"Epilepsia."},{"key":"1675_CR292","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18757-2","volume":"11","author":"S Beesley","year":"2020","unstructured":"Beesley S, Sullenberger T, Crotty K, Ailani R, D\u2019Orio C, Evans K, et al. D-serine mitigates cell loss associated with temporal lobe epilepsy. Nat Commun. 2020;11:4966.","journal-title":"Nat Commun"},{"key":"1675_CR293","first-page":"5757","volume":"14","author":"X Wang","year":"2017","unstructured":"Wang X, He X, Li T, Shu Y, Qi S, Luan G. Anti-epileptic effect of ifenprodil on neocortical pyramidal neurons in patients with malformations of cortical development. Exp Ther Med. 2017;14:5757\u201366.","journal-title":"Exp Ther Med"},{"key":"1675_CR294","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.eplepsyres.2015.09.013","volume":"119","author":"WF Peng","year":"2016","unstructured":"Peng WF, Ding J, Li X, Fan F, Zhang QQ, Wang X. N-methyl-D-aspartate receptor NR2B subunit involved in depression-like behaviours in lithium chloride-pilocarpine chronic rat epilepsy model. Epilepsy Res. 2016;119:77\u201385.","journal-title":"Epilepsy Res"},{"key":"1675_CR295","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.brainresbull.2015.04.002","volume":"114","author":"X Zhu","year":"2015","unstructured":"Zhu X, Dong J, Shen K, Bai Y, Zhang Y, Lv X, et al. NMDA receptor NR2B subunits contribute to PTZ-kindling-induced hippocampal astrocytosis and oxidative stress. Brain Res Bull. 2015;114:70\u20138.","journal-title":"Brain Res Bull"},{"key":"1675_CR296","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nm.2127","volume":"16","author":"M Maroso","year":"2010","unstructured":"Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med. 2010;16:413\u20139.","journal-title":"Nat Med"},{"key":"1675_CR297","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2174\/156802606776894456","volume":"6","author":"I Borza","year":"2006","unstructured":"Borza I, Dom\u00e1ny G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr Top Med Chem. 2006;6:687\u201395.","journal-title":"Curr Top Med Chem"},{"key":"1675_CR298","doi-asserted-by":"crossref","first-page":"e00459","DOI":"10.1002\/prp2.459","volume":"7","author":"D Sciberras","year":"2019","unstructured":"Sciberras D, Otoul C, Lurquin F, Smeraglia J, Lappert A, De Bruyn S, et al. A pharmacokinetic study of radiprodil oral suspension in healthy adults comparing conventional venous blood sampling with two microsampling techniques. Pharmacol Res Perspect. 2019;7:e00459.","journal-title":"Pharmacol Res Perspect"},{"key":"1675_CR299","unstructured":"Perhach J. A randomized, double-blind, placebo- and active-controlled study of the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain [Internet]. clinicaltrials.gov; 2011 Jul [cited 2025 Jun 24]. Report No.: NCT00838799. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00838799"},{"key":"1675_CR300","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.neuropharm.2017.05.017","volume":"123","author":"B Mullier","year":"2017","unstructured":"Mullier B, Wolff C, Sands ZA, Ghisdal P, Muglia P, Kaminski RM, et al. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors. Neuropharmacology. 2017;123:322\u201331.","journal-title":"Neuropharmacology."},{"key":"1675_CR301","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/acn3.50998","volume":"7","author":"S Auvin","year":"2020","unstructured":"Auvin S, Dozi\u00e8res-Puyravel B, Avbersek A, Sciberras D, Collier J, Leclercq K, et al. Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome. Ann Clin Transl Neurol. 2020;7:343\u201352.","journal-title":"Ann Clin Transl Neurol"},{"key":"1675_CR302","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/bph.16361","volume":"181","author":"I Bertocchi","year":"2024","unstructured":"Bertocchi I, Cifarelli L, Oberto A, Eva CE, Sprengel R, Mirza NR, et al. Radiprodil, a selective GluN2B negative allosteric modulator, rescues audiogenic seizures in mice carrying the GluN2A(N615S) mutation. Br J Pharmacol. 2024;181:1886\u201394.","journal-title":"Br J Pharmacol"},{"key":"1675_CR303","unstructured":"UCB Biopharma S.P.R.L. An open-label adaptive study for the assessment of safety, tolerability, pharmacokinetics, and efficacy of multiple doses of radiprodil in subjects with drug-resistant infantile spasms [Internet]. clinicaltrials.gov; 2019 Sep [cited 2025 Jun 24]. Report No.: NCT02829827. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02829827"},{"key":"1675_CR304","unstructured":"GRIN Therapeutics, Inc. A multicenter, open-label study to assess the safety, tolerability, pharmacokinetics, and effect on seizures and behavioral symptoms of radiprodil in patients with tuberous sclerosis complex (TSC) or focal cortical dysplasia (FCD) type II [Internet]. clinicaltrials.gov; 2024 Dec [cited 2025 Jun 24]. Report No.: NCT06392009. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06392009"},{"key":"1675_CR305","unstructured":"Inc GT. GRIN therapeutics announces positive topline data from Honeycomb trial of radiprodil in GRIN-related neurodevelopmental disorder [Internet]. [cited 2025 Jun 24]. Available from: https:\/\/www.prnewswire.com\/news-releases\/grin-therapeutics-announces-positive-topline-data-from-honeycomb-trial-of-radiprodil-in-grin-related-neurodevelopmental-disorder-302240847.html"},{"key":"1675_CR306","unstructured":"GRIN Therapeutics \u2013 Advancing a targeted approach to the treatment of GRIN disorders and other causes of pediatric epilepsy [Internet]. [cited 2025 Jun 24]. Available from: https:\/\/grintherapeutics.com\/"},{"key":"1675_CR307","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1016\/S0140-6736(24)00642-1","volume":"403","author":"NA Hilkens","year":"2024","unstructured":"Hilkens NA, Casolla B, Leung TW, de Leeuw FE. Stroke. Lancet. 2024;403:2820\u201336.","journal-title":"Lancet."},{"key":"1675_CR308","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/17474930241308142","volume":"20","author":"VL Feigin","year":"2025","unstructured":"Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, et al. World Stroke Organization: Global Stroke Fact Sheet 2025. Int J Stroke. 2025;20:132\u201344.","journal-title":"Int J Stroke"},{"key":"1675_CR309","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"SS Virani","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics\u20142021 Update. Circulation. 2021;143:e254\u2013743.","journal-title":"Circulation."},{"key":"1675_CR310","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/01.STR.0000227232.39582.66","volume":"37","author":"CX Fang","year":"2006","unstructured":"Fang CX, Wu S, Ren J. Intracerebral hemorrhage elicits aberration in cardiomyocyte contractile function and intracellular Ca2+ transients. Stroke. 2006;37:1875\u201382.","journal-title":"Stroke."},{"key":"1675_CR311","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10456-021-09796-4","volume":"24","author":"CC Tsao","year":"2021","unstructured":"Tsao CC, Baumann J, Huang SF, Kindler D, Schroeter A, Kachappilly N, et al. Pericyte hypoxia-inducible factor-1 (HIF-1) drives blood-brain barrier disruption and impacts acute ischemic stroke outcome. Angiogenesis. 2021;24:823\u201342.","journal-title":"Angiogenesis."},{"key":"1675_CR312","doi-asserted-by":"crossref","unstructured":"Beccari S, Sierra-Torre V, Valero J, Pereira-Iglesias M, Garc\u00eda-Zaballa M, Soria FN, et al. Microglial phagocytosis dysfunction in stroke is driven by energy depletion and induction of autophagy. Autophagy. 19:1952\u201381.","DOI":"10.1080\/15548627.2023.2165313"},{"key":"1675_CR313","doi-asserted-by":"crossref","first-page":"113125","DOI":"10.1016\/j.biopha.2022.113125","volume":"151","author":"Z Shen","year":"2022","unstructured":"Shen Z, Xiang M, Chen C, Ding F, Wang Y, Shang C, et al. Glutamate excitotoxicity: potential therapeutic target for ischemic stroke. Biomed Pharmacother. 2022;151:113125.","journal-title":"Biomed Pharmacother"},{"key":"1675_CR314","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-022-01064-1","volume":"7","author":"C Qin","year":"2022","unstructured":"Qin C, Yang S, Chu YH, Zhang H, Pang XW, Chen L, et al. Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022;7:215.","journal-title":"Signal Transduct Target Ther"},{"key":"1675_CR315","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature13909","volume":"515","author":"ET Chouchani","year":"2014","unstructured":"Chouchani ET, Pell VR, Gaude E, Aksentijevi\u0107 D, Sundier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515:431\u20135.","journal-title":"Nature."},{"key":"1675_CR316","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/aps.2012.95","volume":"34","author":"NL Weilinger","year":"2013","unstructured":"Weilinger NL, Maslieieva V, Bialecki J, Sridharan SS, Tang PL, Thompson RJ. Ionotropic receptors and ion channels in ischemic neuronal death and dysfunction. Acta Pharmacol Sin. 2013;34:39\u201348.","journal-title":"Acta Pharmacol Sin"},{"key":"1675_CR317","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJM198801283180402","volume":"318","author":"HJ Gelmers","year":"1988","unstructured":"Gelmers HJ, Gorter K, de WCJ, Wiezer HJA. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med. 1988;318:203\u20137.","journal-title":"N Engl J Med"},{"key":"1675_CR318","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1073\/pnas.85.17.6556","volume":"85","author":"JS Hahn","year":"1988","unstructured":"Hahn JS, Aizenman E, Lipton SA. Central mammalian neurons normally resistant to glutamate toxicity are made sensitive by elevated extracellular Ca2+: toxicity is blocked by the N-methyl-D-aspartate antagonist MK-801. Proc Natl Acad Sci USA. 1988;85:6556\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1675_CR319","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/0140-6736(90)92829-7","volume":"336","author":"TS Group","year":"1990","unstructured":"Group TS. Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. Lancet. 1990;336:1205\u20139.","journal-title":"Lancet."},{"key":"1675_CR320","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ana.410270604","volume":"27","author":"R Simon","year":"1990","unstructured":"Simon R, Shiraishi K. N-Methyl-D-Aspartate antagonist reduces stroke size and regional glucose metabolism. Annals Neurol. 1990;27:606\u201311.","journal-title":"Annals Neurol"},{"key":"1675_CR321","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0140-6736(05)62166-6","volume":"349","author":"SM Davis","year":"1997","unstructured":"Davis SM, Albers GW, Diener HC, Lees ER, Norris J. Termination of acute stroke studies involving selfotel treatment. Lancet. 1997;349:32.","journal-title":"Lancet."},{"key":"1675_CR322","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/01.STR.31.2.347","volume":"31","author":"SM Davis","year":"2000","unstructured":"Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, et al. Selfotel in acute ischemic stroke. Stroke. 2000;31:347\u201354.","journal-title":"Stroke."},{"key":"1675_CR323","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1001\/jama.285.13.1719","volume":"285","author":"RL Sacco","year":"2001","unstructured":"Sacco RL, DeRosa JT, Haley EC Jr, Levin B, Ordronneau P, Phillips SJ, et al. Glycine antagonist in neuroprotection for patients with acute stroke GAIN americas: a randomized controlled trial. JAMA. 2001;285:1719\u201328.","journal-title":"JAMA."},{"key":"1675_CR324","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(00)02326-6","volume":"355","author":"KR Lees","year":"2000","unstructured":"Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet. 2000;355:1949\u201354.","journal-title":"Lancet."},{"key":"1675_CR325","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/exnr.1997.6442","volume":"145","author":"F Bordi","year":"1997","unstructured":"Bordi F, Pietra C, Ziviani L, Reggiani A. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAO model of focal ischemia in the rat. Exp Neurol. 1997;145:425\u201333.","journal-title":"Exp Neurol"},{"key":"1675_CR326","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3171\/jns.1997.87.6.0921","volume":"87","author":"A Do\u011fan","year":"1997","unstructured":"Do\u011fan A, Rao AM, Ba\u015fkaya MK, Rao VL, Rastl J, Donaldson D, et al. Effects of ifenprodil, a polyamine site NMDA receptor antagonist, on reperfusion injury after transient focal cerebral ischemia. J Neurosurg. 1997;87:921\u20136.","journal-title":"J Neurosurg"},{"key":"1675_CR327","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0022-3565(25)13281-3","volume":"247","author":"B Gotti","year":"1988","unstructured":"Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J, et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther. 1988;247:1211\u201321.","journal-title":"J Pharmacol Exp Ther"},{"key":"1675_CR328","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1568007053544183","volume":"4","author":"CX Wang","year":"2005","unstructured":"Wang CX, Shuaib A. NMDA\/NR2B selective antagonists in the treatment of ischemic brain injury. Curr Drug Targets CNS Neurol Disord. 2005;4:143\u201351.","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"1675_CR329","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(02)00164-3","volume":"1","author":"C Ikonomidou","year":"2002","unstructured":"Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 2002;1:383\u20136.","journal-title":"Lancet Neurol"},{"key":"1675_CR330","first-page":"CD001244","volume":"2003","author":"KW Muir","year":"2003","unstructured":"Muir KW, Lees KR. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev. 2003;2003:CD001244.","journal-title":"Cochrane Database Syst Rev"},{"key":"1675_CR331","doi-asserted-by":"crossref","first-page":"24151","DOI":"10.1074\/jbc.M113.482000","volume":"288","author":"X Zhou","year":"2013","unstructured":"Zhou X, Ding Q, Chen Z, Yun H, Wang H. Involvement of the GluN2A and GluN2B subunits in synaptic and extrasynaptic N-methyl-D-aspartate receptor function and neuronal excitotoxicity. J Biol Chem. 2013;288:24151\u20139.","journal-title":"J Biol Chem"},{"key":"1675_CR332","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2014.12.007","volume":"112","author":"A Brassai","year":"2015","unstructured":"Brassai A, Suvanjeiev RG, B\u00e1n EG, Lakatos M. Role of synaptic and nonsynaptic glutamate receptors in ischaemia induced neurotoxicity. Brain Res Bull. 2015;112:1\u20136.","journal-title":"Brain Res Bull"},{"key":"1675_CR333","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/sj.jcbfm.9600418","volume":"27","author":"BJ Gwag","year":"2007","unstructured":"Gwag BJ, Lee YA, Ko SY, Lee MJ, Im DS, Yun BS, et al. Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. J Cereb Blood Flow Metab. 2007;27:1142\u201351.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1675_CR334","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.tiv.2012.12.011","volume":"27","author":"NP Visavadiya","year":"2013","unstructured":"Visavadiya NP, McEwen ML, Pandya JD, Sullivan PG, Gwag BJ, Springer JE. Antioxidant properties of Neu2000 on mitochondrial free radicals and oxidative damage. Toxicol Vitr. 2013;27:788\u201397.","journal-title":"Toxicol Vitr"},{"key":"1675_CR335","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1358\/dnp.2010.23.9.1513493","volume":"23","author":"SJ Cho","year":"2010","unstructured":"Cho SJ, Park UJ, Chung JM, Gwag BJ. Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug N Perspect. 2010;23:549.","journal-title":"Drug N Perspect"},{"key":"1675_CR336","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1161\/STROKEAHA.122.039649","volume":"53","author":"JM Hong","year":"2022","unstructured":"Hong JM, Lee JS, Lee YB, Shin DH, Shin DI, Hwang YH, et al. Nelonemdaz for patients with acute ischemic stroke undergoing endovascular reperfusion therapy: a randomized phase II trial. Stroke. 2022;53:3250\u20139.","journal-title":"Stroke."},{"key":"1675_CR337","doi-asserted-by":"crossref","first-page":"e2456535","DOI":"10.1001\/jamanetworkopen.2024.56535","volume":"8","author":"JS Lee","year":"2025","unstructured":"Lee JS, Kang HG, Ahn SH, Song TJ, Shin DI, Bae HJ, et al. Nelonemdaz and patients with acute ischemic stroke and mechanical reperfusion. JAMA Netw Open. 2025;8:e2456535.","journal-title":"JAMA Netw Open"},{"key":"1675_CR338","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5853\/jos.2022.02453","volume":"25","author":"JS Lee","year":"2023","unstructured":"Lee JS, Lee JS, Gwag BJ, Choi DW, An CS, Kang HG, et al. The rescue on reperfusion damage in cerebral infarction by nelonemdaz (RODIN) trial: protocol for a double-blinded clinical trial of nelonemdaz in patients with hyperacute ischemic stroke and endovascular thrombectomy. J Stroke. 2023;25:160\u20138.","journal-title":"J Stroke"},{"key":"1675_CR339","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5853\/jos.2024.05113","volume":"27","author":"JS Lee","year":"2025","unstructured":"Lee JS, Lee JS, Ahn SH, Kang HG, Song TJ, Shin DI, et al. Early administration of nelonemdaz may improve the stroke outcomes in patients with acute stroke. J Stroke. 2025;27:279\u201383.","journal-title":"J Stroke"},{"key":"1675_CR340","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1097\/CCM.0000000000006579","volume":"53","author":"BJ Chun","year":"2025","unstructured":"Chun BJ, Yeom SR, Chung SP, Lee YH, Lee J, Kim YH, et al. Nelonemdaz treatment for patients with out-of-hospital cardiac arrest: a randomized clinical trial. Crit Care Med. 2025;53:e772.","journal-title":"Crit Care Med"},{"key":"1675_CR341","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1124\/jpet.120.000370","volume":"379","author":"SJ Myers","year":"2021","unstructured":"Myers SJ, Ruppa KP, Wilson LJ, Tahirovic YA, Lyuboslavsky P, Menaldino DS, et al. A glutamate N-methyl-D-aspartate (NMDA) receptor subunit 2B\u2013selective inhibitor of NMDA receptor function with enhanced potency at acidic pH and oral bioavailability for clinical use. J Pharmacol Exp Ther. 2021;379:41\u201352.","journal-title":"J Pharmacol Exp Ther"},{"key":"1675_CR342","doi-asserted-by":"crossref","unstructured":"Garcia-Bonilla L. NP10679: A new horizon for neuroprotection in aneurysmal subarachnoid hemorrhage. J Pharmacol Exp Ther [Internet]. 2025 [cited 2025 Jun 24];392. Available from: https:\/\/jpet.aspetjournals.org\/article\/S0022-3565(25)09726-5\/abstract","DOI":"10.1016\/j.jpet.2025.103390"},{"key":"1675_CR343","doi-asserted-by":"crossref","first-page":"100046","DOI":"10.1124\/jpet.124.002334","volume":"392","author":"H Wang","year":"2025","unstructured":"Wang H, Dingledine RJ, Myers SJ, Traynelis SF, Fang C, Tan Y, et al. Clinical development of the GluN2B-selective NMDA receptor inhibitor NP10679 for the treatment of neurologic deficit after subarachnoid hemorrhage. J Pharmacol Exp Ther. 2025;392:100046.","journal-title":"J Pharmacol Exp Ther"},{"key":"1675_CR344","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/cpdd.1217","volume":"12","author":"R Zaczek","year":"2023","unstructured":"Zaczek R, Traynelis SF, Dingledine R, Koszalka GW, Laskowitz DT. Phase 1 clinical results for NP10679, a pH-sensitive GluN2B-selective N-methyl-D-aspartate receptor inhibitor. Clin Pharmacol Drug Dev. 2023;12:706\u201317.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1675_CR345","unstructured":"Neurop Inc. A phase 1, randomized, double blind, multiple ascending dose study to investigate the safety, tolerability and pharmacokinetics of NP10679 in healthy adults\" [Internet]. clinicaltrials.gov; 2019 Nov [cited 2025 Jun 24]. Report No.: NCT04007263. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04007263"},{"key":"1675_CR346","unstructured":"News & Events [Internet]. NeurOp Inc. 2021 [cited 2025 Jun 24]. Available from: http:\/\/www.neuropinc.com\/news-events\/"},{"key":"1675_CR347","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157015908783769671","volume":"6","author":"G Rammes","year":"2008","unstructured":"Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr Neuropharmacol. 2008;6:55\u201378.","journal-title":"Curr Neuropharmacol"},{"key":"1675_CR348","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.2174\/1568026616666160315142457","volume":"16","author":"A Kassenbrock","year":"2016","unstructured":"Kassenbrock A, Vasdev N, Liang SH. Selected PET radioligands for ion channel linked neuroreceptor imaging: focus on GABA, NMDA and nACh receptors. Curr Top Med Chem. 2016;16:1830\u201342.","journal-title":"Curr Top Med Chem"},{"key":"1675_CR349","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2174\/138955710791608299","volume":"10","author":"F Sobrio","year":"2010","unstructured":"Sobrio F, Gilbert G, Perrio C, Barr\u00e9 L, Debruyne D. PET and SPECT imaging of the NMDA receptor system: an overview of radiotracer development. Mini Rev Med Chem. 2010;10:870\u201386.","journal-title":"Mini Rev Med Chem"},{"key":"1675_CR350","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/syn.20415","volume":"61","author":"R Matsumoto","year":"2007","unstructured":"Matsumoto R, Haradahira T, Ito H, Fujimura Y, Seki C, Ikoma Y, et al. Measurement of glycine binding site of N-methyl-D-asparate receptors in living human brain using 4-acetoxy derivative of L-703,717, 4-acetoxy-7-chloro-3-[3-(4-[11c] methoxybenzyl) phenyl]-2(1H)-quinolone (AcL703) with positron emission tomography. Synapse. 2007;61:795\u2013800.","journal-title":"Synapse"},{"key":"1675_CR351","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/acs.jmedchem.8b00714","volume":"62","author":"H Fu","year":"2019","unstructured":"Fu H, Chen Z, Josephson L, Li Z, Liang SH. Positron emission tomography (PET) ligand development for ionotropic glutamate receptors: challenges and opportunities for radiotracer targeting N-methyl-D-aspartate (NMDA), \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate receptors. J Med Chem. 2019;62:403\u201319.","journal-title":"J Med Chem"},{"key":"1675_CR352","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1021\/acs.jmedchem.3c01441","volume":"66","author":"M Korff","year":"2023","unstructured":"Korff M, Chaudhary A, Li Y, Zhou X, Zhao C, Rong J, et al. Synthesis and biological evaluation of enantiomerically pure (R)- and (S)-[18F]OF-NB1 for imaging the GluN2B subunit-containing NMDA receptors. J Med Chem. 2023;66:16018\u201331.","journal-title":"J Med Chem"},{"key":"1675_CR353","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1038\/s41401-025-01571-1","volume":"46","author":"SH Wang","year":"2025","unstructured":"Wang SH, Zeng Y, Yang H, Tian SY, Zhou YQ, Wang L, et al. Discovery of novel GluN1\/GluN3A NMDA receptor inhibitors using a deep learning-based method. Acta Pharmacol Sin. 2025;46:3108\u201315.","journal-title":"Acta Pharmacol Sin"},{"key":"1675_CR354","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1038\/s41401-025-01513-x","volume":"46","author":"ZC Wang","year":"2025","unstructured":"Wang ZC, Zeng Y, Sun JY, Chen XQ, Wu HC, Li YY, et al. An efficient deep learning-based strategy to screen inhibitors for GluN1\/GluN3A receptor. Acta Pharmacol Sin. 2025;46:3099\u2013107.","journal-title":"Acta Pharmacol Sin"},{"key":"1675_CR355","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/s41401-025-01580-0","volume":"46","author":"K Li","year":"2025","unstructured":"Li K, Zeng Y, Xiong Y, da, Wu HC, Fang S, Qu ZY, et al. Contrastive learning-based drug screening model for GluN1\/GluN3A inhibitors. Acta Pharmacol Sin. 2025;46:3116\u201328.","journal-title":"Acta Pharmacol Sin"},{"key":"1675_CR356","doi-asserted-by":"publisher","unstructured":"Li SW, Zeng Y, Wu SN, Ma XY, Xu C, Li ZQ, et al. Discovery of selective GluN1\/GluN3A NMDA receptor inhibitors using integrated AI and physics-based approaches. Acta Pharmacol Sin. 2025. https:\/\/doi.org\/10.1038\/s41401-025-01607-6. Online ahead of print.","DOI":"10.1038\/s41401-025-01607-6"},{"key":"1675_CR357","doi-asserted-by":"publisher","unstructured":"Han L, Zeng Y, Qu ZY, Fang S, Wang HY, Dong YS, et al. Identification of small-molecule inhibitors for GluN1\/GluN3A NMDA receptors via a multiscale CNN-based prediction model. Acta Pharmacol Sin. 2025. https:\/\/doi.org\/10.1038\/s41401-025-01630-7. Online ahead of print.","DOI":"10.1038\/s41401-025-01630-7"},{"key":"1675_CR358","doi-asserted-by":"publisher","unstructured":"Ji YS, Zeng Y, Hu SF, Li SW, Zhang BC, Liu C, et al. AI-enhanced virtual screening approach to hit identification for GluN1\/GluN3A NMDA receptor. Acta Pharmacol Sin. 2025. https:\/\/doi.org\/10.1038\/s41401-025-01644-1. Online ahead of print.","DOI":"10.1038\/s41401-025-01644-1"},{"key":"1675_CR359","doi-asserted-by":"crossref","first-page":"16260","DOI":"10.1021\/acs.jmedchem.5c01173","volume":"68","author":"T Yang","year":"2025","unstructured":"Yang T, Xiong T, Wang Y, Xi B, Liu R, Wang Z, et al. AI-driven discovery and optimization of positive allosteric modulators for NMDA receptors: potential applications in depression. J Med Chem. 2025;68:16260\u201383.","journal-title":"J Med Chem"},{"key":"1675_CR360","doi-asserted-by":"crossref","first-page":"eadq0444","DOI":"10.1126\/sciadv.adq0444","volume":"11","author":"J Zhang","year":"2025","unstructured":"Zhang J, Duan J, Li W, Wang X, Ren S, Ye L, et al. An antidepressant mechanism underlying the allosteric inhibition of GluN2D-incorporated NMDA receptors at GABAergic interneurons. Sci Adv. 2025;11:eadq0444.","journal-title":"Sci Adv"},{"key":"1675_CR361","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/aps.2015.111","volume":"37","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Guo F. Fu Zwen, Zhang B, Huang Cgang, Li Y. Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice. Acta Pharmacol Sin. 2016;37:166\u201376.","journal-title":"Acta Pharmacol Sin"},{"key":"1675_CR362","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41594-023-00959-z","volume":"30","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhang M, Wang Q, Wen H, Liu Z, Wang F, et al. Distinct structure and gating mechanism in diverse NMDA receptors with GluN2C and GluN2D subunits. Nat Struct Mol Biol. 2023;30:629\u201339.","journal-title":"Nat Struct Mol Biol"},{"key":"1675_CR363","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1124\/mol.114.094516","volume":"86","author":"A Khatri","year":"2014","unstructured":"Khatri A, Burger PB, Swanger SA, Hansen KB, Zimmerman S, Karakas E, et al. Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator. Mol Pharmacol. 2014;86:548\u201360.","journal-title":"Mol Pharmacol"},{"key":"1675_CR364","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/schbul\/sbw193","volume":"43","author":"JK Forsyth","year":"2017","unstructured":"Forsyth JK, Bachman P, Mathalon DH, Roach BJ, Ye E, Asarnow RF. Effects of augmenting N-methyl-D-aspartate receptor signaling on working memory and experience-dependent plasticity in schizophrenia: an exploratory study using acute d-cycloserine. Schizophr Bull. 2017;43:1123\u201333.","journal-title":"Schizophr Bull"},{"key":"1675_CR365","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1038\/s41380-022-01498-7","volume":"27","author":"B Lee","year":"2022","unstructured":"Lee B, Pothula S, Wu M, Kang H, Girgenti MJ, Picciotto MR, et al. Positive modulation of N-methyl-D-aspartate receptors in the mPFC reduces the spontaneous recovery of fear. Mol Psychiatry. 2022;27:2580\u20139.","journal-title":"Mol Psychiatry"},{"key":"1675_CR366","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.biopsych.2022.02.106","volume":"91","author":"A Barth","year":"2022","unstructured":"Barth A. NYX-783, a novel positive allosteric modulator of the N-methyl D-aspartate receptor, increases NMDAR-mediated signaling in the infralimbic prefrontal cortex to facilitate extinction learning in PTSD-relevant rodent models. Biol Psychiatry. 2022;91:S35.","journal-title":"Biol Psychiatry"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01675-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01675-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01675-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:23:26Z","timestamp":1767425006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01675-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":366,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1675"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01675-8","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}